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A B S T R A C T
Oxidative DNA damage constitutes a major threat to genetic integrity, and has thus been implicated in the
pathogenesis of a wide variety of diseases, including cancer and neurodegeneration. 7,8-dihydro-8oxo-
deoxyGuanine (8-oxo-G) is one of the best characterised oxidative DNA lesions, and it can give rise to point
mutations due to its miscoding potential that instructs most DNA polymerases (Pols) to preferentially insert
Adenine (A) opposite 8-oxo-G instead of the correct Cytosine (C). If uncorrected, A:8-oxo-G mispairs can give rise
to C:G→ A:T transversion mutations. Cells have evolved a variety of pathways to mitigate the mutational po-
tential of 8-oxo-G that include i) mechanisms to avoid incorporation of oxidized nucleotides into DNA through
nucleotide pool sanitisation enzymes (by MTH1, MTH2, MTH3 and NUDT5), ii) base excision repair (BER) of 8-
oxo-G in DNA (involving MUTYH, OGG1, Pol λ, and other components of the BER machinery), and iii) faithful
bypass of 8-oxo-G lesions during replication (using a switch between replicative Pols and Pol λ). In the following,
the fate of 8-oxo-G in mammalian cells is reviewed in detail. The diﬀerential origins of 8-oxo-G in DNA and its
consequences for genetic stability will be covered. This will be followed by a thorough discussion of the diﬀerent
mechanisms in place to cope with 8-oxo-G with an emphasis on Pol λ-mediated correct bypass of 8-oxo-G during
MUTYH-initiated BER as well as replication across 8-oxo-G. Furthermore, the multitude of mechanisms in place
to regulate key proteins involved in 8-oxo-G repair will be reviewed. Novel functions of 8-oxo-G as an epigenetic-
like regulator and insights into the repair of 8-oxo-G within the cellular context will be touched upon. Finally, a
discussion will outline the relevance of 8-oxo-G and the proteins involved in dealing with 8-oxo-G to human
diseases with a special emphasis on cancer.
1. Introduction: oxidative stress and the chemical instability of
DNA
As with the majority of things in life, there usually is a downside to
even the most positive aspects. The validity of this almost universal
principle holds even when it comes to one of the absolutely central
ingredients of life for most prokaryotic cells and all eukaryotes, namely
oxygen (O2). While all aerobic life is absolutely dependent on O2 to fuel
basic chemical cellular reactions that produce energy and a vast variety
of other essential metabolites, one of the most problematic aspects of O2
consumption comes with its chemically reactive potential that gives rise
to reactive oxygen species (ROS). ROS arise from a variety of sources,
such as oxidative respiration in mitochondria, redox-cycling events
involving Fenton reactions that are mediated by heavy metals, and as
consequence of exposure to ionizing radiation, chemotherapy, transi-
tion metals, chemical oxidants and food (reviewed in [1]). Further-
more, ROS produced by macrophages, neutrophils and certain epithe-
lial cells are essential agents to combat pathogens at the sites of
infections, and also have a key role in inﬂammatory processes [2]. ROS
species present in cells comprise agents such as superoxide anions (%
O2−), hydrogen peroxided (H2O2), and hydroxyl radicals (%OH). Even
though H2O2 is chemically less reactive than some other ROS, it has a
high capacity for damage generation in a cell due to its ability to easily
diﬀuse through biological membranes and thus reach other cellular
compartments very quickly [3]. To counteract or neutralize the gen-
eration of ROS, cells are equipped with a variety of enzymatic and non-
enzymatic antioxidants [4]. However, when the intracellular levels of
ROS rise above the scavenging capacity of these antioxidants, cells
come into a state of oxidative stress. The problem with such states of
oxidative stress is, that ROS can inﬂict damage on many cellular mac-
romolecules, such as proteins, lipids, RNA and DNA. Whereas lipids,
proteins and also RNA can be turned over and replaced entirely rather
easily by resynthesis, damaged DNA cannot [5,6]. In general, oxidative
stress is widely attributed to promote chronic inﬂammation, genomic
instability and human diseases [7].
Albeit being the central coding element that forms the basis of life
(with the exception of RNA viruses), DNA is, chemically speaking, a
remarkably unstable molecule [8]. Damage to DNA can be inﬂicted by
exogenous physical and chemical agents (e.g. UV-irradiation, tobacco
smoke, and DNA methylating agents). However, a detail that often falls
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into oblivion is that, due to its inherent instability, DNA undergoes a
plethora of spontaneous alterations even under absolutely physiological
circumstances and in the absence of any exogenous DNA damaging
agents. This ubiquitous type of DNA damage, mostly referred to as
endogenous DNA damage (as compared to the exogenous type), mostly
originates from spontaneous hydrolytic reactions, as well as the afore-
mentioned intracellular ROS [1]. Indeed, it has been estimated that as
many as 20′000 DNA base lesions are generated every single day in
every single cell under physiological, unstressed conditions through
hydrolysis, oxidation, and non-enzymatic methylation alone [8]. These
lesions, if left unrepaired, pose a serious threat to genetic integrity and
can entail severe adverse consequences, such as cellular dysfunction,
cell death or oncogenic transformation. Thus, genetic integrity is not
only under threat during pathological states, such as oxidative stress,
but is continuously challenged due to the inherent nature of its phy-
siological environment.
2. 8-oxo-G
2.1. 8-oxo-G formation in DNA
While ROS can cause a wide variety of diﬀerent DNA damages in-
volving diﬀerent DNA bases (reviewed in [1]), the base Guanine (G) is
especially vulnerable to oxidation, due to its low redox potential [9].
This leads to the presence of several diﬀerent oxidized G products in
DNA, as well as the ribonucleotide pool, which will be discussed in
Section 2.2. Among the diﬀerent DNA lesions that are generated by
ROS, one of the most abundant and certainly best characterised lesions
is 7,8-dihydro-8-oxo-2′-deoxy-Guanine, or short “8-oxo-G” [9,10]. 8-
oxo-G is generated through the introduction of an oxo group on the
carbon 8 (C8) and the addition of a hydrogen atom to the nitrogen at
position 7 (N7) of deoxy-Guanine (Fig. 1A and B). Estimates of 8-oxo-G
lesions hover around 103 per cell per day under physiological circum-
stances in normal tissues, and values up to 105 lesions/cell have been
reported in cancer cells [11,12]. Indeed, levels of 8-oxo-G are often
used as biomarker to gauge the extent of oxidative stress of individual
cells or organisms, and are even taken into account as a factor in risk
assessment for many diﬀerent diseases including cancer [13]. Due to
certain methodological limitations and the relative propensity of G to
be oxidized into 8-oxo-G even during extraction and quantiﬁcation, not
all of the data regarding 8-oxo-G levels can be taken at face value, but
certainly the plethora of ﬁndings nicely underlines the biological
signiﬁcance of DNA damage caused by ROS.
When present in DNA, the main problem with 8-oxo-G arises during
the cellular S-phase, in which the cell has to produce an accurate copy
of the entire genome, so both daughter cells can inherit the identical
encoded information. In contrast to many other DNA lesions, 8-oxo-G is
not considered a blocking lesion that would stall the progression of the
replication fork [14,15]. Instead, 8-oxo-G functionally mimics a Thy-
mine (T) in syn conformation. This leads to stable formation of a pro-
mutagenic A(anti):8-oxo-G(syn) mispair instead of the non-mutagenic
C(anti):8-oxo-G(anti) base pair [9] (Fig. 1C and D). As a consequence of
this stable A:8-oxo-G Hoogsteen base (mis-)pairing, replicative DNA
polymerases (Pols) eﬃciently and frequently insert the incorrect A
opposite 8-oxo-G instead of the correct C (e.g. [14,16–18] and many
more). More problematically still, the A:8-oxo-G mispair evades
proofreading, the inbuilt error-detection mechanism found in high-ﬁ-
delity replicative Pols, because it mimics a cognate base pair and thus
fails to cause signiﬁcant helix-distortions in the DNA backbone [19].
Instead, the correct C:8-oxo-G Watson-Crick base pair is recognized as a
mismatch, which consequently leads to a much lower eﬃciency of C
incorporation opposite 8-oxo-G and explains the mutagenic properties
of this lesion. If the A:8-oxo-G mispair goes uncorrected, one of the
daughter cells will obtain a DNA template that harbours a point mu-
tation at the site of 8-oxo-G, thus inheriting a C:G→ A:T transversion
mutation (Fig. 2A). Concluding, A inserted opposite 8-oxo-G acts si-
milarly to a wolf in sheep’s clothing by pretending to be a correct base
pair, while being a common source for point mutations in reality. The
details of repair of 8-oxo-G will be discussed in Section 4.
2.2. 8-oxo-G formation in the nucleotide pool
As essential building blocks for life, desoxyribonucleotides (dNTPs),
the precursors of DNA are not exempt from the threat emanating from
ROS. Apart from attacking DNA bases directly, as discussed above, ROS
also cause oxidation of the dNTP pool present in cells. As starting
material to build DNA, oxidatively (or otherwise) damaged dNTPs pose
a serious threat for genetic integrity when incorporated into nascent
DNA either during DNA replication or repair. Indeed, dGTP seems to be
even more susceptible to oxidation than G in DNA [20]. Thus, the
problem of 8-oxo-G formation in DNA does not only arise from oxida-
tion of a C:G base pair, but also from transactions that necessitate
synthesis of new DNA where oxidatively damaged 8-oxo-dGTP can be
incorporated opposite undamaged templating bases (Fig. 2B).
Fig. 1. Structures of 8-oxo-Guanine and its base-pairs. A) and B):
Chemical structure of A) unaltered Guanine and B) 8-oxo-
Guanine. The residues of 8-oxo-G that diﬀer from normal G and
are involved in base-pairing are coloured red. C) and D): Chemical
structure of C) 8-oxo-G:C Watson-Crick and D) 8-oxo-G:A
Hoogsteen base pairs. The hydrogen bonds contributing to base
pairing are indicated by yellow dashed lines.
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Currently there are 17 known human Pols that, as the name sug-
gests, polymerise growing chains of DNA by incorporation of dNTPs
opposite a DNA template [21,22]. Depending on its speciﬁc properties,
each of these Pols will intrinsically incorporate damaged nucleotides
with a diﬀerent propensity. Determinants for incorporation of damaged
nucleotides are features of the Pol itself, such as the structure of the
active site and its relative ‘ﬂexibility’ or ‘rigidity’ to accommodate and
productively process unconventional base pairings, the structure of the
nucleotide binding pocket, as well as the access of the respective Pol to
the site of DNA synthesis. This last aspect is important to remember, as,
regardless how promiscuous a certain Pol might be, if it does not gain
access to actually perform DNA synthesis, it will not be able to do harm.
From this, one can directly infer the importance of a very tight reg-
ulation especially of the more promiscuous Pols, as will be discussed in
detail in Section 5. Though nature has devised mechanisms to reduce
the burden of 8-oxo-dGTP in the nucleotide pool (see Section 4.3),
nevertheless the incorporation of oxidatively damaged dNTPs poses a
real threat to genetic integrity [23,24].
Incorporation of 8-oxo-dGTP has been shown to be catalysed by
many diﬀerent Pols across all families and reverse transcriptases into
DNA and RNA, and the incorporation eﬃciencies as well as preference
for either a templating A or C depend on the individual Pol and whether
8-oxo-dGTP adapts a syn or anti conformation during base pairing (e.g.
[24–37] and Table 1). Incorporation of 8-oxo-dGTP by Pols has been
shown to generate A:T→ C:G mutations (Fig. 2B) [38–41]. The pre-
ferences of diﬀerent Pols to incorporate 8-oxo-dGTP opposite tem-
plating A or C are summarized in Table 1.
As has been discussed above in Section 2.1, a Watson-Crick C:8-oxo-
G pairing causes template and polymerase distortions and thus rather
poses problems than the Hoogsteen base pairing adapted by A:8-oxo-G
[19], which is consistent with Pols in general preferentially inserting 8-
oxo-dGTP opposite templating A (Table 1 and references therein). Of
note, this lower preference for insertion of 8-oxo-dGTP opposite C
caused problems to crystallize a complex of 8-oxo-dGTP paired to C for
a long time, while crystals of A:8-oxo-dGTP were achievable. Structural
studies suggest that while the ﬂexibility around the template-binding
pocket of a Pol can permit 8-oxo-G to base pair both in Watson-Crick as
well as Hoogsteen base pairing, the binding pocket for incoming nu-
cleotides does not have such ﬂexibility and thus strongly discourages
insertion of 8-oxo-dGTP opposite C, as demonstrated for Pol β [55].
Finally, insertion of 8-oxo-dGTP opposite either templating base by Pol
β has been shown to lead to a cytotoxic nicked repair intermediate due
to loss of hydrogen-bonding interactions between the bases that causes
DNA synthesis to pause [45]. In contrast, another study found that li-
gation after 8-oxo-dGTP insertion by Pol β into a single nucleotide gap
by DNA ligase I was productive in the context of both templating bases,
though possibly a bit less eﬃcient when 8-oxo-dGTP was inserted op-
posite C [43]. Overall, it seems that the proofreading activity of 8-oxo-
dGTP inserted opposite A depends highly on the Pol in question, and
possibly also the experimental reaction conditions used to probe this
question.
The problem succeeding insertion of 8-oxo-dGTP into nascent DNA
is outlined in the following: if 8-oxo-dGTP is inserted opposite C, re-
moval of 8-oxo-G from C:8-oxo-G base pairs is relatively unproblematic
through activity of the 8-oxo-G speciﬁc DNA glycosylase OGG1, as
discussed in detail in Section 4.1. If however 8-oxo-dGTP is inserted
opposite A (Fig. 2B), repair of the resulting A:8-oxo-G base pair faces a
conundrum: A:8-oxo-G base pairs are the substrate for DNA glycosylase
MUTYH, which excises the A from A:8-oxo-G base pairs [56]. Yet, such
MUTYH-catalysed excision of A and subsequent replacement with C (as
discussed in detail in Section 4.1) would result in ﬁxation of the wrong
C:8-oxo-G base pair in this particular situation. Thus, 8-oxo-dGTP in-
sertion into DNA has the potential to lead to A:T→ C:G transversion
mutations. Indeed, 8-oxo-dGTP has been shown to cause such
A:T→ C:G transversions in mammalian cells [57,58]. To circumvent
such mutations, it is assumed that cells would opt to avoid activity of
MUTYH in these situations. Instead, to resolve this state of aﬀairs,
mismatch repair potentially steps in at this point, as discussed later in
Sections 4.2 and 8.3.
In light of the obvious preference of many Pols to insert 8-oxo-G
opposite the incorrect A, it comes as somewhat of a relief to know that
the eﬃciency to incorporate 8-oxo-dGTP instead of the normal dNTPs is
Fig. 2. Mechanism of 8-oxo-Guanine-induced mutations. 8-oxo-G
can be introduced into DNA through 2 diﬀerent mechanisms. A)
Reactive oxygen species (ROS) can directly attack DNA, thus
causing oxidation of G in the context of C:G which forms C:8-oxo-
G base pairs. If replication across 8-oxo-G occurs, 8-oxo-G is often
bypassed erroneously and A is inserted, giving rise to A:8-oxo-G
base pairs. If left uncorrected, a 2nd round of replication will lead
to ﬁxation of a A:T base pair. Such a scenario leads to C:G→ A:T
transversion mutations. B) ROS can also cause oxidation of the
nucleotide pool, thus giving rise to 8-oxo-dGTP (odGTP), which
can be inserted opposite A to yield an A:8-oxo-G base pair.
Replication or inappropriate MUTYH-initiated excision of A from
A:8-oxo-G base pairs can cause C:8-oxo-G base pairs to form. C:8-
oxo-G base pairs are substrate for OGG1-mediated repair, which
removes the 8-oxo-G and replaces it with a G, giving rise to an
A:T→ C:G transversion mutation.
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rather low, especially for the replicative DNA Pols of the B-family that
have been tested so far (Table 2). Nevertheless, the danger of in-
corporating 8-oxo-dGTP during transactions carried out by Pols should
not be underestimated.
Some of the open questions in the ﬁeld are which of the Pols leads to
incorporation of 8-oxo-dGTP into DNA in vivo, under which
circumstances this happens, and whether insertion of an 8-oxo-dGTP by
replicative Pols triggers proofreading activity or even initiates a Pol
switch to continuously promote DNA synthesis. Furthermore, it would
be interesting to get an understanding for the exact amounts of oxidized
nucleotides present in cells under speciﬁc circumstances.
Among the possible culprits, for obvious reasons, the more pro-
miscuous repair Pols have been investigated for their contribution to 8-
oxo-dGTP insertion. Pol β, Pol η, REV1, Pol ζ, Pol κ have all been im-
plicated to have their share in catalysing 8-oxo-dGTP incorporation into
DNA in vivo. Nevertheless, also the replicative Pols − by nature much
less prone to catalyse incorrect insertion of nucleotides − might con-
tribute to this phenomenon (reviewed in [60]). It thus remains to be
addressed how exactly cells deal with such situations to alleviate both
the mutational as well as the potentially cytotoxic potential that results
from 8-oxo-dGTP insertion.
3. DNA base excision repair
To counteract the possibly deleterious eﬀects that DNA damage and
mutations can have, cells have evolved an intricate network of DNA
repair pathways that constantly sense, report and correct aberrations in
DNA caused by all kinds of endogenous and exogenous DNA damage
[61]. The major cellular repair pathway responsible for repair of the
majority of DNA lesions deriving from endogenous sources, such as
ROS, is base excision repair (BER). The task of BER is to repair the
multitude of frequent, constantly arising DNA base alterations and
single-strand breaks (SSBs), prompting a comparison with the role of a
cellular housekeeper engaged to keep genomic DNA tidy and clean
[62]. Interestingly, it seems that cells have diﬃculties living without
their housekeeper: knocking out any of the core BER pathway genes
(APE1, XRCC1, Pol β, or DNA ligase III) is embryonically lethal (see also
Table 3 and the relevant text sections) [62]. This has been widely at-
tributed as clear evidence for the importance of not having too much
DNA damage in cells in order to survive. It might however also be at
least partly caused by the fact, that the core BER machinery is critically
involved in active DNA demethylation, a crucial mechanism involved in
embryonic development [63].
Depending on the nature of the lesion that needs to be taken care of,
Table 1
Templating base preference for incorporation of 8-oxo-dGTP by various Pols.
Favoured template DNA Polymerase DNA Pol Family Template preference dA/dC Refs.
dA > > > dC hPolι Y dA only [30]
hPolη Y >180:1, 660:1 [30,37]
Dbh (Sulfolobus solfataricus) Y dA only [42]
Dpo4 (Sulfolobus solfataricus) Y dA only [42]
dA > dC hPolβ X 10.5:1, 24:1, 40:1 [43–45]
hPolλ X 34.5:1, 4.5:1 [36,43]
hPolγ A 13:1, 66.7:1 [46,47]
hPolκ Y 11:1 [37]
T7exo− (T7 bacteriophage) A 31:1 [26]
Pol III (Escherichia coli) C 20:1 [41]
Pol IV (Escherichia coli) Y N.d. [48]
Pol I BF (Bacillus stearothermophilus) A 12.7:1 [33]
Pol X (Thermus thermophilus) X 43.3:1 [34]
DinB2 (Mycobacterium smegmatis) Y N.d. [49]
dA ≅ dC Pol4 (Schizosaccharomyces pombe) X 1.08:1 [35]
KFexo− (Escherichia coli) A 1.6:1, 0.44:1 [26,50]
α subunit Pol III (Escherichia coli) C 1.3:1 [51]
HIV-1 RT (Human Immunodeﬁciency virus) RT 0.5:1 [26]
ASFV Pol X (African swine fever virus) X 0.5:1 [29]
φ29 Pol (Bacillus subtilis phage φ29) B 0.33:1 [52]
DNA Pol B1 (Sulfolobus solfataricus) B N.d. [42]
dA < dC hPolα B 0.146:1 [33]
Bovine Polδ+PCNA B 0.032:1 [53]
Pol II exo− (Escherichia coli) B 0.045:1 [26]
Table modiﬁed after [54]. The ratio dA/dC is the ratio of eﬃciency of 8-oxo-dGTP incorporation opposite templating dA or dC, as determined from kcat/km, vmax/km or kpol/kd. ‘h’ before
Pol stands for human. N.d. = ratio could not be determined. RT = reverse transcriptase.
Table 2
Relative eﬃciencies of various DNA Polymerases for incorporating 8-oxo-dGTP compared
to incorporation of normal dNTPs.
DNA Polymerase DNA Pol
Family
Eﬃciency of 8-oxo-
dGTP incorporation
Refs.
hPolγ A 1 × 10−4 [46]
KFexo− (Escherichia coli) A 1.2 × 10−2 [26]
7.2 × 10−4 [50]
6.4 × 10−6 [59]
T7exo− (T7 bacteriophage) A 9.1 × 10−6 [26]
Pol I BF (Bacillus
stearothermophilus)
A 1.07 [33]
hPolα B 7.3 × 10−4 [33]
Bovine Polα B 1.5 × 10−2 [59]
Bovine Polδ+PCNA B ∼10−3 [53]
φ29 Pol (Bacillus subtilis phage
φ29)
B 5.0 × 10−4 [52]
Pol II exo− (Escherichia coli) B 3.1 × 10−6 [26]
Pol III (Escherichia coli) C 5.6 × 10−2 [41]
α subunit Pol III (Escherichia coli) C 3.9 × 10−2 [51]
hPolβ X 1.8 × 10−1 [43]
8.0 × 10−3 [44]
hPolλ X 4.7 × 10−3 [36]
7.5 × 10−2 [43]
Pol X (Thermus thermophilus) X 6.5 × 10−2 [34]
Pol4 (Schizosaccharomyces pombe) X 4.04 × 10−2 [35]
ASFV Pol X (African swine fever
virus)
X 1.3 × 10−3 [29]
hPolι Y 1.7 × 10−2 [30]
hPolη Y 1.5 × 10−1 [30]
5.9 × 10−1 [37]
hPolκ Y 7.9 × 10−3 [37]
Table modiﬁed after [54]. The eﬃciency of 8-oxo-dGTP incorporation opposite the fa-
vourite templating base compared to incorporation of normal dNTPs opposite that same
base, as determined from kcat/km, vmax/km or kpol/kd. ‘h’ before Pol stands for human.
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BER can proceed via two diﬀerent repair subpathways, short-patch
(replacing only the damaged nucleotide) or long-patch BER (which
replaces a stretch of 2–12 nucleotides starting at the damaged site)
(Fig. 3) [62]. The classical short-patch BER pathway is initiated by one
of the many diﬀerent DNA glycosylases present in cells, each of which
recognizes a subset of diﬀerent damaged bases [64]. Depending on the
identity of the glycosylase, it only catalyses the release of the corrupted
base by hydrolysis of the N-glycosylic bond that links the DNA base to
its sugar backbone, thus creating an abasic site (AP-site), or promotes
further incision of the phosphodiester backbone to yield a 1 nucleotide
gap with modiﬁed DNA termini. The resulting intermediates are further
processed by AP-endonuclease 1 (APE1), Polynucleotide phosphatase/
kinase (PNKP), or other ‘end processing enzymes’ which tailor the DNA
ends to be compatible with DNA synthesis and ligation. At this point,
classical BER converges with repair of SSBs, which are another type of
lesion very frequently formed by ROS [65]. As the name suggests, SSBs
are discontinuities in one strand of the DNA double helix, usually ac-
companied by loss of a single nucleotide and often harbouring chemi-
cally modiﬁed DNA termini surrounding the break. Once the 3′ ter-
minus has been “cleaned up” to be an OH group (prerequisite for Pols to
insert a nucleotide), the so-called core BER complex consisting of Pol β
(Pol β), X-ray repair cross-complementing protein 1 (XRCC1), and DNA
ligase IIIa (Lig IIIa) steps into action. Pol β utilizes its dRP-lyase activity
to remove the downstream 5′sugar phosphate and inserts one nucleo-
tide into the gap, whereupon Lig IIIa catalyses ligation of the 3′OH
group of the newly inserted nucleotide with the downstream 5′P, thus
completing the short-patch BER subpathway. If the 5′-ends are blocked
and cannot be processed by the available end-processing enzymes, BER
can proceed via a long-patch sub-pathway, that leads to a replacement
of 2–12 nucleotides and utilizes a switch from Pol β to the replicative
Pol δ [62]. In this scenario, the displaced DNA ﬂap of 2–12 nucleotides
is cut oﬀ by ﬂap endonuclease 1 (FEN1) and ligation occurs through
DNA ligase I.
4. Dealing with 8-oxo-G
As discussed in Section 2, ROS can lead to direct formation of 8-oxo-
G in DNA, as well as give rise to the oxidation product 8-oxo-dGTP
nucleotide pool. To keep the mutational burden stemming from these
two sources of oxidized G in check, organisms employ various enzyme
systems designed to counteract this oxidative threat. Mechanisms to
subdue the mutational burden of these oxidized G products involve
repair of 8-oxo-G that can be found in DNA, removal of oxidized nu-
cleotides from the ribonucleotide pool to avoid their incorporation into
nascent DNA, as well as ways for the replication fork to correctly bypass
8-oxo-G lesions encountered during replication (Fig. 4). The variety of
contexts that 8-oxo-G can be found in reﬂects directly in the variety of
mechanisms that have been described to be utilized for repair, removal
or bypass of 8-oxo-G damage. In the following, the diﬀerent mechan-
isms utilized by the cell to lower the impact of 8-oxo-G in these diverse
contexts will be discussed.
4.1. Base excision repair of 8-oxo-G in DNA
The bulk of 8-oxo-G lesions in genomic DNA are dealt with by BER,
and this involves a multistep process as well as the involvement of
diﬀerent key players depending on whether A:8-oxo-G or C:8-oxo-G
base pairs are the substrate to be addressed (Fig. 5). Additional me-
chanisms that contribute to repair of 8-oxo-G in DNA are discussed in
Section 4.2.
In principle, C:8-oxo-G base pairs can be formed whenever oxidative
stress impinges on double-stranded DNA and leads to oxidation of G in
the context of a C:G base pair. The fate of this newly formed C:8-oxo-G
base pair is now much dependent on the cell cycle: if this particular
stretch of DNA is not currently undergoing replication, the DNA gly-
cosylase OGG1 is capable of recognizing C:8-oxo-G base pairs and
subsequently remove 8-oxo-G. The resulting 1 nucleotide gap is then
processed by APE1 and the canonical BER core complex Pol β – XRCC1
– Lig IIIa restores a fully double-stranded piece of DNA containing a
Fig. 3. Simpliﬁed schematic overview of Base Excision Repair.
Modiﬁed from [198]. (A) BER is initiated by damage-speciﬁc DNA
glycosylases, which identify and release the corrupted base by hy-
drolysis of the N-glycosylic bond linking the DNA base to the sugar
phosphate backbone (reviewed in [229]). The arising abasic (AP) site
is further processed by AP-endonuclease 1 (APE1), and depending on
the mechanism by which the DNA base was removed, end processing
of the modiﬁed 3′- and 5′-termini is performed by a variety of end-
processing enzymes. This processing results in the generation of a 3′-
OH and a 5′-P group adjacent to the DNA gap or break. (B) Single-
strand breaks (SSBs) can also arise from direct disintegration of oxi-
dized deoxyribose. This process usually leads to damaged or modiﬁed
termini, which are processed by a variety of enzymes to 3′-OH and 5′-
P groups. SSBs are then handled identically to the BER intermediates
from this point onward. (C) Further processing of the SSB containing
intermediate stemming from either source is carried out by the core
BER complex. Shown here is the short-patch BER subpathway that
includes DNA polymerase β (Pol β), XRCC1 (X-ray repair cross-com-
plementation group 1) and DNA ligase IIIa (Lig III). Pol β possesses a
dRP-lyase activity that removes the 5′-sugar phosphate and also,
functioning as a DNA polymerase, adds one nucleotide to the 3′-end of
the arising single-nucleotide gap. Finally, the XRCC1-Lig III complex
seals the DNA ends, therefore accomplishing complete DNA repair
[62].
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correctly repaired G:C base pair (reviewed in [1]). If however the C:8-
oxo-G base pair escapes repair and is utilized uncorrected as a template
for DNA synthesis, replicative Pols frequently insert a wrong A opposite
8-oxo-G instead of the correct C, as discussed in Section 2. This gives
rise to an A:8-oxo-G mispair. Importantly, the nucleotide that needs to
be removed now is the undamaged A, and not the 8-oxo-G, because
another round of replication would lead to ﬁxation of the mutation in
the form of a TA base pair, having caused a C:G→ A:T transversion
mutation. To remove the erroneously incorporated A from an A:8-oxo-G
base pair, cells utilize the DNA glycosylase MUTYH [56]. MUTYH is a
slightly unconventional glycosylase in that it does not remove a da-
maged nucleotide from DNA, but rather the undamaged A from oppo-
site a damaged 8-oxo-G. This very important enzyme gives the cells ‘a
second chance’ to correct what was wrongly inserted opposite 8-oxo-G
Fig. 4. The various ways to deal with 8-oxo-G. Cells
employ 3 major pathways to deal with 8-oxo-G: nu-
cleotide pool sanitisation, base excision repair (BER)
of 8-oxo-G in DNA, and bypass of 8-oxo-G during
replication by a DNA polymerase switch. (A) dGTP in
the nucleotide pool is prone to oxidation by reactive
oxygen species (ROS), giving rise to 8-oxo-dGTP
(odGTP). The four enzymes MTH1, MTH2, MTH3
and NUDT5 catalyse hydrolysis of 8-oxo-dGTP to
produce the monophosphate compound 8-oxo-dGMP
(odGMP) and thus remove 8-oxo-dGTP from the nu-
cleotide pool. MTH1 is highlighted in bold, because
current evidence suggests that it has by far the most
important role in sanitisation of 8-oxo-dGTP in mammalian cells. (B) ROS also attack DNA, causing oxidation of C:G which forms C:8-oxo-G base pairs. If replication across 8-oxo-G
occurs, 8-oxo-G is often bypassed erroneously and A is inserted, giving rise to A:8-oxo-G base pairs. (C) C:8-oxo-G base pairs are substrate for OGG1-initiated BER, while A:8-oxo-G
mispairs are processed through MUTYH-initiated BER. These two BER processes are discussed more in detail in Fig. 5. (D) Replication across 8-oxo-G can have two outcomes: insertion of
correct C or incorrect A opposite 8-oxo-G. (left) Error-free bypass of 8-oxo-G by a replicative polymerase (Repl. Pol) is promoted by exchanging the Repl. Pol with Pol λ after insertion of
correct dCTP. Pol λ is capable of preferentially extending C:8-oxo-G base pairs for a few nucleotides, after which Pol λ is replaced again by the Repl. Pol. (right) Incorrect bypass of 8-oxo-
G instead is promoted by exchanging the Repl. Pol with Pols β or η after insertion of incorrect dATP. Pols β and η preferentially extend the wrong A:8-oxo-G base pairs for a few
nucleotides, after which a switch back to the Repl. Pol occurs. For simplicity, only Pol β is indicated in the image, but Pol η has been shown to have the same eﬀect.
Fig. 5. MUTYH-initiated BER of A:8-oxo-G lesions. Modiﬁed from [56]. When ROS attack DNA, this leads to the formation of C:8-oxo-G base pairs through oxidation of G. (left column)
These can be recognized by OGG1, which excises the 8-oxo-G and incises the resulting AP-site by β-elimination, giving rise to a 3′ddR5P and a 5′P residue. This 3′ sugar phosphate is then
removed by APE1, yielding a 1 nucleotide gap with a 3′OH and a 5′P. Subsequently, pol β catalyses the insertion of a G opposite the templating C in this SP-BER pathway, and ligation by
XRCC1/DNA ligase III leads to restoration of an intact, correctly base-paired double-stranded DNA again. (middle column) If the C:8-oxo-G base pairs are not recognized before S-phase by
OGG1, or they arise through oxidation in S-phase, the replicative pols will often incorporate a wrong A opposite 8-oxo-G, giving rise to A:8-oxo-G mispairs. If these are not corrected,
another round of replication will lead to a C:G- > A:T transversion mutation. (right column) The A:8-oxo-G base pairs can be recognized by MUTYH, which catalyses the excision of the
wrong A from opposite 8-oxo-G, leading to the formation of an AP site. This AP site is further processed by APE1, which results in a 1 nt gap with 3′OH and 5′dRP moieties. The
incorporation of the correct C opposite 8-oxo-G and one more nucleotide is performed by pol λ in collaboration with the cofactors PCNA and RP-A, thus performing strand displacement of
the downstream DNA strand. FEN1 cleaves the 5′ ﬂap, leading to a 5′P moiety, which can be ligated by DNA ligase I to yield an intact C:8-oxo-G containing double-stranded DNA. This
C:8-oxo-G is then again substrate for OGG1-mediated removal of 8-oxo-G (left column).
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in the ﬁrst place. By doing so, MUTYH paves the way for a long-patch
BER subpathway [16,66,67]. As in canonical BER, removal of the base
by MUTYH is followed by tailoring of the DNA ends by APE1, so that a
Pol can insert the correct C opposite 8-oxo-G. Nevertheless, as discussed
already in Section 2, insertion of C opposite 8-oxo-G is something most
Pols ﬁnd diﬃcult to do. Thus it was unclear for a long time, which Pol is
responsible for inserting the correct nucleotide, as most examined pols
showed signiﬁcant error-prone bypass of 8-oxo-G. Over the last decade,
accumulating evidence has clearly shown that Pol λ, a close relative of
Pol β, is the one Pol to eﬃciently insert a correct C opposite 8-oxo-G
when helped by the two cofactors Proliferating Cell Nuclear Antigen
(PCNA) and Replication Protein A (RP-A) [16]. In fact, Pol λ together
with PCNA and RP-A inserted 1200-fold more correct C opposite 8-oxo-
G than incorrect A. Later on, this unique ability of Pol λ to catalyse C:8-
oxo-G base pairs was found to result from a very ﬂexible active site,
capable of accommodating 8-oxo-G in both the anti and syn con-
formations, and from a kinetic switch that selectively discriminates
against the pro-mutagenic syn conformation, thus shunting repair to-
ward the correct C:8-oxo-G base pairing [68]. Interestingly, the aux-
iliary proteins PCNA and RP-A were found to act as molecular switches
in this context to activate the error-free Pol λ-dependent 8-oxo-G by-
pass while at the same time repressing error-prone bypass by the ca-
nonical BER enzyme Pol β [66]. This Pol λ-mediated error-free repair of
A:8-oxo-G mismatches was shown to utilize a long-patch BER me-
chanism by additionally replacing 1 nucleotide downstream from the
original lesion, and thus require FEN1 as well as DNA ligase I to come to
successful completion [67]. The resulting product of this error-free
MUTYH and Pol λ-mediated repair pathway of A:8-oxo-G mismatches is
an C:8-oxo-G base pair, which in turn is amenable to the OGG1-initiated
short-patch BER reaction, as discussed above.
4.2. Additional mechanisms contributing to repair of 8-oxo-G in DNA
While repair of 8-oxo-G lesions in DNA is dominated by OGG1- and
MUTYH- initiated BER, other DNA repair pathways have been found to
contribute to keep the mutational burden of 8-oxo-G as low as possible.
The list of involved players includes mismatch repair (MMR), tran-
scription-coupled nucleotide excision repair (TC-NER), global-genome
nucleotide excision repair (GG-NER), as well as a variety of other DNA
glycosylases, as has been reviewed in detail in [1,69,70].
Mounting evidence suggests that the involvement of MMR in
keeping 8-oxo-G levels in DNA under control is potentially via removing
8-oxo-G from 8-oxo-G:A mismatches that have arisen due to insertion of
8-oxo-dGTP. As already mentioned, the problem with insertion of 8-
oxo-dGTP into nascent DNA is the following: if inserted opposite C,
removal of 8-oxo-G from C:8-oxo-G base pairs should be relatively
straight forward through activity of the 8-oxo-G speciﬁc DNA glyco-
sylase OGG1, as discussed in the previous chapter. If however inserted
opposite A (Fig. 2B), MUTYH-initiated repair of the resulting A:8-oxo-G
base pair faces a problem: excision of A from A:8-oxo-G base pairs and
subsequent replacement with C would result in ﬁxation of the wrong 8-
oxo-G:C base pair in this particular situation and lead to an A:T→ C:G
transversion mutation. To avoid this, it is assumed that cells would opt
to avoid activity of MUTYH in these situations. Instead, to resolve this
state of aﬀairs, mismatch repair has shown to contribute to removal of
8-oxo-G that has arisen from insertion of 8-oxo-dGTP [23,59,71]. As
MMR is closely linked to replication and one of its main functions is the
correction of replication-caused mistakes by targeting its removal ac-
tivity to the nascent strand, utilising MMR in this case seems an elegant
solution to the problem. This would also explain the apparent sy-
nergistic action of MUTYH-initiated BER and MMR that has been often
seen in vivo, as discussed later in Section 8.3. Details on this interaction
between MUTYH and the MMR pathway have been reviewed recently
in [60]. How the coordination between these diﬀerent pathways is
achieved to ensure proper processing of these lesions in the context of
DNA replication still remains far from being understood.
4.3. Removal of 8-oxo-dGTP from the nucleotide pool
Removal of 8-oxo-dGTP from the nucleotide pools before it gets
incorporated into DNA by Pols is an important pathway for safekeeping
the genome from 8-oxo-G damage. To date there are 4 enzymes that
have been described to catalyse the hydrolysis of a variety of diﬀerent
oxidised nucleotides including 8-oxo-dGTP: MutT homologue 1 (MTH1,
sometimes referred to as NUDT1), MutT homologue 2 (MTH2, also
known as NUDT15), MutT homologue 3 (MTH3 or NUDT18) and
Nudix-type 5 (NUDT5) (Fig. 4A). These enzymes can catalyse the hy-
drolysis of 8-oxo-dGTP to 8-oxo-dGDP or 8-oxo-dGMP. As 8-oxo-dGMP
cannot be used by Pols for DNA synthesis, this hydrolysis prevents in-
corporation of 8-oxo-dGTP into nascent DNA. The ﬁnal degradation
product, 8-oxo-dGMP, can not be reutilized either to produce 8-oxo-
dGTP via phosphorylation through guanylate kinase, as this enzyme is
not active on 8-oxo-dGMP (reviewed in [72]). Overall, current evidence
suggests that MTH1 is the most important contributor to nucleotide
pool sanitisation of 8-oxo-dGTP in mammalian cells, and the other three
enzymes might play a backup-role for this nucleotide, while being re-
levant in the processing of other substrates. For an in-depth discussion
of these enzymes the interested reader is referred to a recent review on
pathways that control dNTP pools [60]. In summary, removal of 8-oxo-
dGTP from the nucleotide pool is an important mechanism to mitigate
the mutational potential of oxidised nucleotides that can otherwise be
erroneously incorporated by Pols into DNA.
4.4. Bypass of 8-oxo-G during replication
Error-free replication of DNA is a very basic prerequisite of life for
cells to divide and entire organisms to stay healthy. In an ideal world,
all C:8-oxo-G base pairs would be repaired before the onset of re-
plication. As however oxidation of G can occur throughout the entire
cell cycle, DNA in S-phase is by no means exempt from the threat of
ROS-induced DNA damage, such as 8-oxo-G. Thus, a scenario that has
to be dealt with by the cell is the bypass of 8-oxo-G lesions during DNA
replication.
As already discussed above, in contrast to many other DNA lesions,
such as for instance UV-induced lesions that present a block to re-
plicative Pols (reviewed e.g. in [73]), 8-oxo-G is not considered a
blocking lesion per se [14,15,74]. Nevertheless, transient inhibition of
DNA synthesis by diﬀerent Pols (such as the Klenow fragment of Es-
cherichia coli Pol I and calf thymus Pols α and δ) occurring 3′ to the
templating 8-oxo-G has been documented, indicating that these Pols do
slightly struggle with the lesion all the same [14,53]. Similarly, pol δ
from human cells has been shown to transiently stall at sites of 8-oxo-G
lesions [75]. Therefore, 8-oxo-G is not a stalling lesion, but still induces
the replicative Pols to slow down during bypass. Furthermore, the E.coli
Pol I Klenow fragment as well as calf thymus Pols α and δ were found to
struggle with extension of correct C:8-oxo-G base pair and much more
eﬃciently extended A:8-oxo-G mispairs [14,53]. Despite these dire
prospects when replicative Pols encounter an 8-oxo-G, the overall in
vivo mutation frequency of 8-oxo-G lesions in templating DNA without
post-replication repair mechanisms has been estimated at around 19%,
which is much lower than expected considering the replication bypass
problems [74]. Therefore, a very central question emerges: how is
correct bypass of 8-oxo-G by the replication machinery accomplished,
when insertion of correct C opposite 8-oxo-G by replicative Pols is so
hard to achieve and the extension of correct C:8-oxo-G base pairs so
diﬃcult? Addressing this exact question, it was found that human Pol δ
pauses in front of 8-oxo-G, and then readily incorporates both C or A
opposite the lesion [76]. When it came to extending past the lesion,
however, the A:8-oxo-G mispairs were easily extended by Pol δ, in stark
contrast to C:8-oxo-G base pairs, which led to stalling of Pol δ. It was
further shown that the stalling of Pol δ after incorporation of correct C
opposite 8-oxo-G could be overcome by Pol λ, Pol β, and Pol η, all of
which assisted Pol δ to overcome the lesion. Most importantly,
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however, these results demonstrated that only Pol λ was able to assist
Pol δ to selectively perform the correct insertion of C opposite 8-oxo-G
by speciﬁcally enhancing exclusively the correct bypass of 8-oxo-G
using C, while Pols β and η lacked selectivity and even preferentially
enhanced erroneous bypass of 8-oxo-G. These data suggested the ex-
istence of a DNA polymerase-switch between the replicative Pol δ and
the repair Pol λ to promote error-free bypass of 8-oxo-G lesions in an
eﬃcient and accurate manner to counteract the mutational potential of
8-oxo-G (Fig. 4D). Indeed, Pol λ had been shown to preferentially ex-
tend C:8-oxo-G base pairs, with an eﬃciency even higher than that
displayed on undamaged C:G base pairs [77]. Pol λ’s unique proﬁciency
to insert correct C opposite 8-oxo-G and preferentially extend C:8-oxo-G
base pairs was shown to be courtesy of Pol λ’s unique ﬂexible active site
and a speciﬁc kinetic switch that discriminates against pro-mutagenic
bypass [68]. Interestingly, corroborating a possible role of Pol λ either
directly at or shortly following the replication fork, silencing of Pol λ,
but not Pol β, was found to cause replication stress and to activate the S-
phase checkpoint [78]. Indeed, an impairment of the S-phase check-
point was synthetically lethal when combined with silencing of Pol λ in
cancer cells. More recently, the existence of a DNA polymerase-switch
between a replicative Pol and Pol λ that promotes error-free bypass of
8-oxo-G lesions has been independently conﬁrmed [79]. Signiﬁcantly,
as had been observed initially [76], this study also reported an increase
in small deletions at the site of 8-oxo-G when Pol λ was absent from the
cells. These ﬁndings are in line with a role of Pol λ in extending the C:8-
oxo-G base pair for a few nucleotides, which, as discussed above is a
feature replicative Pols struggle with. Once the C:8-oxo-G base pair has
been extended by Pol λ suﬃciently, the replicative Pols take over again
to continue replication as usual. Searching for factors responsible of
inﬂuencing this DNA polymerase-switch between Pol δ and Pol λ at 8-
oxo-G lesions, it was found that Pol δ interacting protein 2 (PolDIP2)
could physically interact with Pol λ and thus increase both the pro-
cessivity as well as the catalytic eﬃciency of the error-free bypass of 8-
oxo-G by Pol λ as well as Pol η [80].
Among the many questions that remain open are: how exactly is the
switch between Pol δ and Pol λ coordinated during replication? Do
PCNA and RP-A have a modulatory role in this? While mono-ubiquiti-
nation of PCNA was not found to inﬂuence the switch reaction [76],
how does the replication fork signal the need to switch Pols at 8-oxo-G?
These and many other details regarding the synthesis past 8-oxo-G will
hopefully be clariﬁed in the future.
4.5. Incorporation of rNMPs opposite 8-oxo-G
Despite their speciﬁcity, replicative Pols incorporate rNMPs during
DNA replication to a very signiﬁcant extent [81–84]. Estimates range
up to 1′000′000 rNMPs being incorporated during the replication of a
mammalian genome. While such rNMP incorporation can serve in as-
sisting discrimination between the templating and the newly synthe-
sized DNA strand for certain repair purposes (e.g. mismatch repair
[85,86]), the presence of less stable rNMPs in DNA constitutes a serious
threat to genome stability. This is mainly due to the sugar backbone of
RNA being much more prone to strand breakage compared to DNA,
which can potentially result in accumulation of strand breaks in such a
DNA-RNA hybrid molecule.
While several groups have addressed the propensity and selectivity
of diﬀerent Pols to incorporate rNMPs opposite canonical DNA bases
mainly in the context of replication (reviewed in [87]), a very inter-
esting twist to the plot comes from several studies that have assessed
the incorporation of rNMP opposite 8-oxo-G. Analysis of Pol4 from
S.pombe revealed that this enzyme bypasses 8-oxo-G lesions almost
exclusively through insertion of rATP, generating a rA:8-oxo-G base
pair, which becomes substrate for eﬃcient removal by RNase H2 [35].
RNAse H2-mediated excision then paves the way for another chance to
incorporate correct dCTP opposite 8-oxo-G. This is a very interesting
ﬁnding, and it remains to be seen whether a similar mechanism
operates in human cells as well. Of note, bypass of 8-oxo-G using NTPs
was also documented for DinB2, a Y-family Pol from M. smegmatis [49].
Using human enzymes, a study that compared the rNMP insertion ﬁ-
delities of Pols β and λ opposite 8-oxo-G found that both Pols were
capable of inserting rNMPs both opposite the cognate undamaged
templating bases as well as opposite 8-oxo-G [88]. The insertion ﬁdelity
opposite 8-oxo-G however diﬀered between the Pols and depended on
the template. While Pol λ still preferentially inserted rCMP opposite 8-
oxo-G as opposed to rAMP in a substrate mimicking a 1-nucleotide
gapped BER intermediate, this preference was entirely lost when a
substrate without downstream primer was provided, suggesting that the
DNA template inﬂuences selectivity of Pol λ in this scenario. Pol β on
the other hand showed lower selectivity than Pol λ for incorporation of
rCMP versus rAMP opposite 8-oxo-G in a 1-nt-gap, whereas it showed
better bypass ﬁdelity in a non-gapped template than Pol λ. Incorpora-
tion of ribonucleotides opposite 8-oxo-G impaired the functions of both
OGG1 and MUTYH, thus potentially impairing 8-oxo-G repair. Finally,
experiments with cell extracts of wild-type and knockout cells to repair
the gapped template then demonstrated that Pol β was the main re-
sponsible for incorporation of rCMP opposite 8-oxo-G. Thus, an addi-
tional problem for dealing with 8-oxo-G comes from incorporation of
rNMPs opposite the lesion, which can inﬂuence the repair activities
downstream quite substantially. In a follow-up study, it was shown that
Pol η can incorporate rCMP opposite 8-oxo-G and diﬀerent other da-
maged guanine products, an activity which was enhanced by its aux-
iliary factor PolDIP2 [89]. Subsequent removal of ribonucleotides by
RNAse H2 was less eﬃcient for rCMP and rGMP than the other ribo-
nucleotides, and rCMP opposite DNA lesions further reduced RNAse
H2-mediated ribonucleotide removal. Experiments using cell extracts
indicated that translesion synthesis by Pol η can contribute to accu-
mulation of rCMP in the genome, particularly opposite modiﬁed G
products. It will be of high interest to further elucidate the diﬀerential
contributions of the various Pols to incorporation of rNMPs opposite
damaged bases, and to understand the repair mechanisms in place.
5. Regulation of the key players in 8-oxo-G repair
5.1. Keeping the balance: too little versus too much
Levels of BER proteins can vary considerably between diﬀerent
tissues and individuals [90]. Precise regulation of BER proteins is of
paramount importance to genetic stability, as demonstrated by various
lines of evidence (Fig. 6). To support eﬃcient and error-free cellular
transactions, BER proteins have to be available at suﬃcient levels to
repair DNA damage within a reasonable amount of time. If levels of BER
proteins are too low or their activity is too weak to deal with damage
present in the cell, this has a negative impact on genome stability and
cell viability. Indeed, mutations that aﬀect either protein amounts or
the enzymatic activity of BER proteins lead to a reduction in cell via-
bility, an increase in genomic instability and can lead to cancer
[91–95]. On the contrary, while too little repair activity is not optimal,
too much of it can also be detrimental. Pols that speciﬁcally evolved to
perform DNA repair, so-called repair Pols, intrinsically harbour a much
lower ﬁdelity for DNA synthesis compared to replicative Pols. This is
due to their active sites having adapted to accommodate a wide variety
of diﬀerent damaged bases, so that they are capable of dealing with
unconventional base pairings [22]. If let loose on long undamaged
stretches of DNA, these repair Pols could cause many point mutations
by mis-incorporation of nucleotides because of their less stringent
‘quality criteria and quality control’ for correct base pairing of un-
damaged DNA bases. Indeed, it has been shown that Pol β can interfere
with synthesis of the lagging strand, which leads to lowered replication
ﬁdelity [96]. Also, overexpression of Pol β in cells increases their sen-
sitivity to genotoxic treatments, such as ionizing radiation and sur-
viving cells display a hypermutator phenotype [97]. Further support for
this hypothesis comes from various reports that show deregulation of
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diﬀerent repair Pols, including Pols λ and β, can lead to diseases in
general, and cancer in particular [98,99]. Interestingly, it has been
shown that repair Pols are overexpressed in many tumours, and might
thus contribute to disease manifestation [100]. Thus, these important
repair enzymes have to be under tight control to guarantee that they
only are active when really needed. While such tight regulation is of
utmost importance for Pols involved in DNA repair, the same principle
can in eﬀect be extended to the entire BER pathway. In summary, it is
important for cells to ﬁt their BER capacity to their individual need, as a
mismatch between supply and demand can result in compromised
viability or induction of mutations. Considering all these facts, it seems
nothing but logical to infer that levels of BER proteins should undergo
constant adjustment to ﬁt individual needs in response to the cellular
environment.
Slowly, regulatory mechanisms controlling BER enzymes are be-
ginning to be revealed. In general, there are several diﬀerent features
that a cell can modulate to control (not only) BER components: abun-
dance, activity, and subcellular localisation. In the following, the most
important points about the regulation of key players involved in repair
of 8-oxo-G will be summarised.
5.2. Regulation of OGG1
The regulation of OGG1 has been widely investigated by multiple
approaches. Mechanisms include regulation of protein activity, protein
turnover, and subcellular localization, and some of these features are
inﬂuenced by posttranslational modiﬁcations, such as acetylation and
phosphorylation. Additionally, there are plenty of sometimes con-
ﬂicting reports about transcriptional control of OGG1 upon exposure to
genotoxic treatments. A thorough review of these mechanisms con-
tributing to regulation of OGG1 can be found in [1]. More recent evi-
dence can be added to the picture, as discussed in the following.
Transcriptional up-regulation of OGG1 has been shown to be triggered
by diﬀerent signalling molecules, such as: 5′-AMP-activated protein
kinase (AMPK) activated by rapamycin-mediated inhibition of mam-
malian target of rapamycin (mTOR) [101], activation of the oxidative-
stress responsive transcriptional activator nuclear factor erythroid 2-
related factor 2 (NRF2) [102,103], as well as the transcription factor
Nuclear transcription factor Y subunit alpha (NF-YA) (e.g.
[101,104,105]). Also, Breast cancer susceptibility gene 1 (BRCA1) has
been implicated in transcriptional regulation of OGG1 [106]. And in-
terestingly, levels of OGG1 have recently been shown to be subject to
circadian modulation [107]. In a group of 15 healthy volunteers, the
authors found higher levels of OGG1 in the morning compared to the
evening, which went in hand with 8-oxo-G repair activity as well, and a
signiﬁcant shift was found in a group of shift-workers experiencing a
deregulation of circadian clock genes compared to the control group.
These results suggest, that circadian modulation of 8-oxo-G repair by
control of OGG1 levels could inﬂuence the susceptibility to oxidative
stress at diﬀerent points during the day, hinting at yet another layer of
complexity in regulating DNA repair of oxidative damage.
To conclude, OGG1 can be regulated on many diﬀerent levels, and
the inducibility of OGG1 transcription through oxidative or other stress
seems to be somewhat tissue- and cell-type speciﬁc. More insights on
the exact orchestration of how to ﬁt the supply of this important DNA
glycosylase to the speciﬁc cellular needs will be much appreciated.
5.3. Regulation of MUTYH
The DNA glycosylase MUTYH is a protein that is regulated in a cell-
cycle dependent manner, reaching a maximum in S-phase, and co-lo-
calizing together with PCNA to replication foci [108]. This obviously S-
phase dependent expression and localization pattern was corroborated
by a 14-fold higher repair eﬃciency by using a replication-proﬁcient
DNA substrate compared to a non-replicating one [109]. Adjustment of
MUTYH levels to cellular needs has been described to be achieved by
transcriptional regulation as well as regulation by posttranslational
modiﬁcations, either leading to a change in its glycosylase activity or its
aﬃnity to bind DNA. The details on these regulatory mechanisms have
been thoroughly reviewed in [56]. More recently, MUTYH protein le-
vels were found to be directly regulated by the E3 ligase Mule, med-
iating poly-ubiquitin-chain addition to MUTYH to orchestrate its pro-
teasomal degradation [110].
It is interesting to note that the E3 ligase targeting MUTYH for
proteasomal degradation is also the one involved in the decay of its
close ‘collaborator’ Pol λ (see Section 5.6 about regulation of DNA
polymerase λ). Also, the cell-cycle dependence of MUTYH levels and
activity is in perfect alignment with its cellular role in processing A:8-
oxo-G mismatches, that result mainly from DNA replication across 8-
oxo-G lesions, as discussed above. Given the clear replication-associated
role of MUYH, underlined by its co-localization with PCNA to replica-
tion foci, and its interaction with components of the replication ma-
chinery, like PCNA, MSH2/MSH6 and RP-A, it would be interesting to
know more about the exact orchestration of A:8-oxo-G excision during
replication and/or repair. Further insights into the mechanism of reg-
ulation of this pivotal protein for A:8-oxo-G repair would certainly
advance our understanding of how exactly cells deal with the muta-
tional threat posed by 8-oxo-G.
5.4. Regulation of APE1
The endonuclease APE1 is attributed to be responsible for most of
Fig. 6. The importance of correctly balancing DNA repair. (left) in-
adequate protein levels or hampered enzymatic activity of DNA repair
enzymes lead to impairments in DNA repair. A direct consequence of in-
suﬃcient DNA repair is the accumulation of mutations in DNA, which
contributes to the onset of ageing, cell death as well as disease. (right)
when DNA repair protein levels are too high or the enzymes overactive
due to misregulation, they can interfere with normal cellular DNA trans-
actions, such as e.g. DNA replication. This can cause introduction of
random DNA damage or mutations, and in turn lead to the onset of ageing,
cell death as well as disease. It is therefore highly important to keep the
DNA repair activities under tight control and closely adapted to the cel-
lular need.
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the AP-site cleavage activity taking place in mammalian cells
[111,112]. While this makes APE1 an essential enzyme for BER, the ﬂip
side of the coin is that APE1, which is an extremely active enzyme, is
responsible for the generation of the majority of SSBs produced in the
wake of BER [113]. This suggests that APE1 activity requires to be
strictly matched with following repair by the core BER complex to re-
solve any SSBs that are produced by APE1 in a timely fashion. Loss of
such thigh regulation of the BER pathway has been suggested to be
linked with genomic instability [114,115]. Indeed, increased levels of
APE1 have been shown to induce genomic instability, most probably
through a lack of coordination with downstream BER activity and re-
sulting generation of an overload of SSBs [116,117]. Furthermore, the
connection between APE1 levels and tumour aggressiveness and prog-
nosis is well established (reviewed in [118,119]). Thus, precise reg-
ulation of APE1 levels seems to be of high importance for genetic in-
tegrity.
APE1 is regulated at many diﬀerent levels: modulation of APE1
transcription, changes in its subcellular localization (e.g. from the nu-
cleus to the cytoplasm), and by modulation of its posttranslational
modiﬁcations, which in turn can impact on subcellular localization,
activity and/or protein stability (reviewed in [120–122]). For instance,
ATF4-dependent transcriptional regulation of APE1 upon arsenite ex-
posure of cells has been reported [123], and H2O2-inducible tran-
scription of APE1, among other BER enzymes, was suggested to be
mediated by BRCA1 [106]. Also, PARP1 was implicated in control of
mitochondrial repair proteins, among which MUTYH and APE1, by
localizing to the promoter regions and exerting epigenetic control
[124]. Furthermore, p53 was demonstrated to mediate down-regulation
of APE1 transcription after genotoxic stress in the form of camptothecin
treatment [125]. Similarly, it has been recently shown that a p53-
mediated transcriptional control mechanism acting via destabilization
of the transcription factor Sp1 allows the adjustment of APE1 levels to
the load of DNA damage present in cells [126]. The APE1 protein pool
can be controlled by the E3 ubiquitin ligase UBR3, which poly-ubi-
quitinates APE1, thus targeting it for proteasomal degradation [117].
Among control mechanisms of subcellular localization of APE1 S-ni-
trosoglutathion, a S-nitrosating agent, was found to eﬃciently promote
export of APE1 from the nucleus to the cytoplasm by way of mod-
iﬁcation of Cys93 and Cys310 of APE1, thus possibly inhibiting its DNA-
dependent activities [127]. Furthermore, nucleophosmin was shown to
modulate APE1 enzymatic activity [128]. Finally, as a cellular redox
factor, APE1 itself can also regulate the levels and activity of other DNA
repair proteins, as it can modify several downstream transcription
factors (reviewed in [129]).
Thus, control of APE1 is a multi-layered, complicated process far
from being completely understood. This beﬁts the general notion that a
tight control of this important enzyme has to be exerted to ensure
cellular health.
5.5. Regulation of DNA polymerase β
In general, Pol β is viewed as being constitutively expressed – akin
to a “housekeeping” enzyme – in most cells [130]. This is perfectly in
line with its role as the ‘canonical BER Pol’ whose activity is required in
many diﬀerent scenarios all throughout the cell cycle to ensure repair of
abundantly occurring small base lesions and SSBs. While transcription
of Pol β has been reported to be inducible in response to certain types of
exogenously applied DNA damaging agents (e.g. [131]), other authors
question whether expression of BER components is inducible (e.g.
[126,132,133]). It is probably reasonable to assume that the in-
ducibility of Pol β is much dependent on the tissue and cell type, akin to
OGG1.
Apart from transcriptional control, precise control of Pol β steady-
state protein levels, and in fact the entire core BER complex, is achieved
using an elegant multi-layered mechanism that links protein levels with
levels of endogenously occurring DNA damage and entails multiple
levels of control. Pol β can be bound in a repair-proﬁcient core complex
with XRCC1 and Lig III in cells [134]. Importantly, the stability of this
protein complex is determined by the presence of the scaﬀolding pro-
tein XRCC1, a reductions in XRCC1 levels (e.g. by siRNA or by genetic
ablation) lead to reductions in the levels of Pol β and Lig III
[115,132,134,135]. Superﬂuous BER proteins not bound in a complex
are targeted by two diﬀerent E3 ubiquitin ligases called Mule/ARF-BP1
and CHIP: ﬁrstly, Mule adds a monoubiquitin to ‘prime’ the protein for
subsequent ubiquitination and, secondly, CHIP extends this ubiquitin
chain, thus labelling the target for proteasomal degradation [134,136].
Interestingly, the activity of Mule can be inhibited by the tumour
suppressor ARF, which accumulates in response to DNA damage
[137,138] by a transcriptional regulation through a PARP1-SIRT1-E2F1
axis [132]. Inhibition of Mule activity by ARF binding results in accu-
mulation of active Pol β – XRCC1 – Lig III complexes able undertake
DNA repair. A subsequent drop in DNA damage load due to repair re-
sults in turn in reduced ARF transcription, activating the Mule-depen-
dent degradation of superﬂuous BER complexes. Additionally, Mule
undergoes constant self-ubiquitination, which targets it for proteasomal
degradation. This can be counteracted through USP7S-dependent de-
ubiquitination under physiological circumstances, thus preventing
Mule from degradation and enabling it to orchestrate the degradation of
Pol β in turn. Upon DNA damage, USP7S is down-regulated, which
leads to destabilisation of Mule and subsequent stabilisation of the BER
complex [139].
Summarizing, though considered a constitutively expressed protein,
steady-state Pol β levels get constantly adapted to the cellular need by
matching the supply to the demand, which in turn is determined by the
amount of DNA damage that is present in the cell. This ﬁne-tuning
ensures that the core BER complex is available at suﬃcient levels to
optimally perform its job, while still keeping a tight regulation to avoid
exaggerated activity.
5.6. Regulation of DNA polymerase λ
Initial investigations into the mechanism that regulates Pol λ levels
started with the identiﬁcation of the S-phase kinase complex cyclin-
dependent kinase 2 (Cdk2)/Cyclin A as novel interaction partner for Pol
λ [140]. Cdk2/Cyclin A was found to phosphorylate Pol λmainly in the
S, G2 and M-phase of the cell cycle. Phosphorylation occurred at four
distinct residues and was shown to lead to stabilization of Pol λ by
protecting it from degradation via the ubiquitin-proteasome system
[141]. Subsequently the two E3 ligases CHIP and Mule were identiﬁed
as capable of ubiquitinating Pol λ in vitro [142]. While the relevance of
CHIP-mediated ubiquitination of Pol λ in vivo remains to be clariﬁed, it
was conﬁrmed that Mule is responsible for ubiquitin-dependent de-
gradation of Pol λ in cells [143]. In contrast, while not changing the
enzymatic nucleotide selectivity towards 8-oxo-G [122], phosphoryla-
tion of Pol λ by Cdk2/Cyclin A leads to a recruitment of Pol λ to
chromatin by enhancing its interaction with chromatin-bound MUTYH
to form active 8-oxo-G repair complexes. S-phase recruitment of Pol λ
to chromatin was even increased upon oxidative stress, suggesting that
this mechanism is in place to guarantee the availability of productive
repair complexes at the exact time that A:8-oxo-G mismatches are being
produced: during replication.
It is interesting to note that, like its ‘partner’ MUTYH (discussed
above in Section 5.3), Pol λ seems to be primarily needed on chromatin
during S-phase, while its close relative, Pol β, is considered more of a
housekeeping enzyme active all through the cell cycle. Thus, a picture
slowly emerges in which Pol λ has at least two distinct roles during the
S-phase: ﬁrstly, it helps the replication fork to correctly bypass 8-oxo-G
lesions by engaging in a polymerase switch with replicative Pols (dis-
cussed in Section 4.4 and Fig. 4D), and secondly, together with MUTYH
it is responsible for correction of erroneous A:8-oxo-G mispairs that
have been produced during replication (discussed in Section 4.1 and
Fig. 5).
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5.7. Regulation of XRCC1
It is interesting, that while Pol β is often considered a housekeeping
enzyme, the protein partner that supports its stability and activity,
XRCC1, is usually not put into this same category. Indeed, transcription
of XRCC1 was reported to be enhanced following DNA damage upon
ionizing radiation, as well as via EGF signalling through the EGFR and
MAPK pathways [144,145]. Furthermore, an MMS-triggered up-reg-
ulation of XRCC1 transcription via E2F1 has been documented [146].
E2F1 has also been reported to regulate XRCC1 levels in context of the
cell cycle [147]. While the basal levels of XRCC1 were reported to be
under the control of PI3K-AKT, induction of XRCC1 expression after
ionizing radiation was suggested to be MKK1/2-ERK1/2 dependent in
A549 cells [148]. On the contrary, low doses of ionizing radiation did
not seem to induce XRCC1 expression in TK6 cells [133]. Chk2-medi-
ated stabilisation of the fork-head box M1 (FoxM1) transcription factor
was shown to promote transcription of XRCC1 in response to DNA
damage by etoposide, IR or UV [149].
XRCC1 can be post-translationally modiﬁed by phosphorylation,
SUMOylation, poly-ADP-ribosylation and ubiquitination.
Phosphorylation of XRCC1 by Casein Kinase 2 (CK2) was shown to be
essential to enable the assembly and activity of XRCC1-repair com-
plexes and promote its dissociation from DNA [150–154]. Mutation of
the site of poly-ADP-ribosylation protects XRCC1 from ubiquitination
and thus proteasomal degradation [154]. Moreover, XRCC1 is SU-
MOylated [155] and ubiquitination of XRCC1 by the E3 ligase CHIP
leads to proteasomal degradation of the protein [134,135,156,157].
Phosphorylation of XRCC1 was found to be prerequisite for such poly-
ubiquitination [154]. Finally, interactions of XRCC1 with aprataxin
[158], PNKP [159] as well as HSP90 [135,160] were reported to sta-
bilize the XRCC1 protein.
Taken together, there are quite a few reports investigating the
regulation of XRCC1 levels in the cellular context, but we are still far
from understanding completely all intricacies of its regulation and how
it is related to tissue- or cell type and state.
5.8. Regulation of DNA ligases I and III
Details on the regulation of DNA ligases I and III have been thor-
oughly reviewed in [161]. Mechanisms include transcriptional regula-
tion upon genotoxic treatments (e.g. [162]), regulation of its activity
and protein partner binding by phosphorylation (e.g. [163–165]) and
dephosphorylation (e.g. [166]), and poly-ubiquitin mediated protea-
somal degradation [134,167].
5.9. Regulation of nucleotide pool sanitization enzymes
Except for MTH1, there is no data on regulation of the levels of the
other nucleotide pool sanitization enzymes MTH2, MTH3 or NUTD5.
For MTH1, intracellular localization of the protein is dependent on its
isoform and alternative splicing (reviewed in [168]). Despite the fact
that higher levels of MTH1 have generally been observed in cancerous
cells compared to normal cells (discussed in [169]), the cell cycle or
proliferation rate of cells was not found to inﬂuence activity of MTH1
[169]. The up-regulation of MTH1 in cancer cells was thus suggested to
be a result of increased oxidative stress in cancer cells [170]. Indeed,
up-regulation of MTH1 on mRNA, protein as well as its activity level
has been described after exposure of cells to diﬀerent agents that induce
oxidative stress, as discussed in [171]. Furthermore, it was even shown
that 8-oxo-G in complex with OGG1 (representing the product of OGG1-
mediated 8-oxo-G excision from DNA) is capable of inducing tran-
scription of MTH1, but not MTH2 [172]. It thus seems that cells are
capable to regulate the availability of MTH1 in response to the levels of
oxidation stress within reasonable limits.
Concluding, regulation of the diﬀerent key proteins involved in
repair of 8-oxo-G is diversiﬁed and highly complex. Frequent
diﬀerences in ﬁndings regarding inducibility of transcripts or protein
levels might well be due to diﬀerences between cell and tissue types,
cell cycle stages, use of primary versus transformed cells as well as
culturing conditions, which could have huge impacts on the baseline
levels of DNA damage and the concomitant level of response towards
the respective treatments. Clearly, the ﬁeld would proﬁt from deeper
analysis of some of these issues.
6. 8-oxo-G repair in the cellular context
One important aspect of regulation of repair activity that has not
addressed so far is the inﬂuence of chromatin remodelling on the ac-
tivity of BER in general, and repair of oxidative DNA damage in par-
ticular.
If DNA was simply an elongated loose molecule freely ﬂoating in the
cell, DNA repair of any particular region would be easily feasible any-
where anytime, provided that the right proteins would ﬁnd their sub-
strate in an orderly fashion. However, within the nucleus, DNA is never
present as a linear molecule. Instead, it is highly organized into a
complex structure called chromatin that consists of DNA, histones and
many other proteins forming complexes that guarantee the correct
spatial and structural arrangement of this huge, compact molecule.
Most probably, this complex arrangement of DNA actually also is a
prerequisite for correct execution of DNA maintenance and transac-
tions, making sure that factors working together are targeted to the
right sequences at the right time. Due to the complexity of this struc-
ture, it seems nothing but logical that the accessibility for DNA repair
complexes in general, and BER of oxidative DNA damage in particular,
can be modulated by diﬀerent chromatin conﬁgurations. Indeed, there
is evidence that chromatin remodelling mediated by the de-ubiquiti-
nating enzyme USP7 is important for BER of oxidative lesions, as
transient USP7 knockdown did not change the levels or activity of BER
enzymes, but signiﬁcantly reduced accessibility and consequently the
repair rate of oxidative lesions [173]. Not only the chromatin status but
also the cellular diﬀerentiation state seems to play a role in determining
its capacity for oxidative BER, as shown in a study using un-
diﬀerentiated embryonic stem (ES) cells or ES cells diﬀerentiated for 0,
4 and 7 days [174]. Amounts of 8-oxo-G and expression levels of OGG1,
MUTYH and MTH1 in the cells were measured after H2O2 treatment.
While levels of MTH1 and MUTYH remained unchanged, the amounts
of OGG1 decreased with increasing diﬀerentiation, which was con-
comitant with an accumulation of 8-oxo-G in those cells, suggesting ES
cells were more resistant to oxidative stress than diﬀerentiated cells.
While the question how BER is organised in the context of chromatin in
vivo clearly holds high relevance, there seem to be more questions than
answers at the current point in time. Recent reviews of literature re-
garding the interplay between chromatin remodelling and BER, along
with a discussion of the complications that arise with the study of this
subject, can be found in [175,176].
Another area of research focuses on the occurrence and repair of
oxidation damage in telomeric DNA, the extremities of chromosomes.
OGG1 was also found to repair 8-oxo-G lesions occurring in the G-rich
telomeric DNA by BER, and ablation of OGG1 in S.cerevisiae led to an
increase in 8-oxo-G in telomeric DNA and induced telomere length-
ening by telomerase/Rad52 mediated homologous recombination
[177]. These results suggested that 8-oxo-G could disturb telomere
length equilibrium by interfering with telomere length maintenance,
which may be one of the mechanisms by which oxidative stress da-
mages the genome. Another report analysed the inﬂuence of 8-oxo-G
repair by OGG1 on mammalian telomeres in ogg1 -/- mouse tissues and
primary MEFs under various oxidative culturing conditions [178].
Cultivation at 3% oxygen, assumed to be hypoxic conditions, led to
telomere lengthening, whereas telomeres shortened in hematopoietic
cells and primary MEFs when cultivated in the presence of an oxidant or
under normoxic conditions (20% oxygen). Other abnormalities, such as
telomere length abnormalities, telomere sister chromatid exchanges,
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increased telomere SSBs and DSBs, and others were observed, in-
dicating that 8-oxo-G damage that arises in telomeres, can aﬀect proper
telomere maintenance. Similarly, a study examining the susceptibility
of telomeric DNA to oxidative base damage demonstrated telomeric
TTAGGG repeats to be more prone to oxidative base damage and re-
paired less eﬃciently than non-telomeric TG repeats in vivo [179]. The
activity of OGG1 was similar in telomeric and non-telomeric double-
stranded substrates and not impaired by telomere repeat binding factors
Trf1 and Trf2. However, in certain speciﬁc telomeric structures, 8-oxo-
G was less eﬀectively excised by OGG1, depending on its position
within these substrates. Collectively, these data indicated the sequence
context of telomeric repeats and certain telomeric conﬁgurations to
contribute to telomere vulnerability during oxidative DNA damage
processing. Telomeric DNA can form quadruplex DNA structures in vitro
and possibly also in vivo. One report suggested that the two glycosylases
NEIL1 and NEIL3 are capable of removing a variety of oxidative DNA
lesions from telomeres and other quadruplex DNA containing contexts
[180]. Both glycosylases did not show activity to remove 8-oxo-G from
DNA, however. A follow-up of this work conﬁrmed that, in contrast to
other oxidative lesions, 8-oxo-G could not be removed from telomeric
quadruplexed DNA by either NEIL1, NEIL3 or OGG1, but all three NEIL
glycosylases readily excise damage from telomeric and promoter DNA
quadruplex structures [181], suggesting that these glycosylases might
be involved in both maintenance of telomeres as well as gene regula-
tion. Interestingly, while oxidative DNA damage was shown to be
completely repaired in the rest of the genome, it was found to persist in
telomeric regions of human primary ﬁbroblasts, and to induce sig-
niﬁcant temporary telomere shortening as well as increased chromo-
somal instability within 48 h after oxidative stress, which was restored
to almost normal values subsequently [182]. These results suggested a
correlation between oxidative DNA damage, telomere length, and ab-
normal nuclear morphologies induced by chromosome instability.
Moreover, 8-oxo-dGTP insertion by telomerase was shown to terminate
further elongation of the telomere, while presence of 8-oxo-G in the
telomere sequence promoted telomerase activity through destabilisa-
tion of the G-quadruplex DNA structure [183]. Thus, the mechanism by
which 8-oxo-G is introduced into telomeres seems to dictate its biolo-
gical outcome in the context of telomere lengthening or shortening.
Overall, these results highlight the vast diﬀerences of sequence and
structure context, chromatin context and biological outcomes of 8-oxo-
G in DNA, and warrant future studies to further elucidate the con-
tribution of 8-oxo-G in physiological and pathological states in vivo.
7. 8-oxo-G as an epigenetic-like regulator
Presence of DNA damage in a gene can signiﬁcantly modulate its
expression by either directly interfering with transcription or as a
consequence of interference between attempts to repair the damage
that clashes with transcriptional activity [184]. While 8-oxo-G in DNA
has so far been viewed mainly in the light of being pro-mutagenic and
thus potentially detrimental to cells, more recent research has also
uncovered a more physiological aspect of 8-oxo-G presence in DNA in
the control of gene transcription.
8-oxo-G in template DNA was shown to stall transcription by RNA
Pol II [185]. Also, a single 8-oxo-G located in the non-transcribed DNA
strand of a reporter gene was shown to have a strong negative eﬀect on
transcription, suggesting that induction of transcriptional silencing
serves ubiquitously as a mode of biological response to 8-oxo-G in DNA
[186]. On the other hand, several reports demonstrated that 8-oxo-G
induced by oxidative stress could go in hand with increased gene ex-
pression [187,188]. Further work then unveiled that 8-oxo-G localized
in the promoter regions of various genes could cause a transcriptional
increase via the BER pathway [189–191]. Thus, it seems as though 8-
oxo-G may have a regulatory role in cells undergoing oxidative stress
and thus display “epigenetic-like” features in regulation of gene tran-
scription. Indeed, by studying the exact location of 8-oxo-G in mouse
embryonic ﬁbroblasts through sequencing, regulatory gene elements
such as gene promoters and un-translated regions were found to contain
more 8-oxo-G enriched sites than expected to occur by stochastic dis-
tribution of the damage, further underlining the possible role of 8-oxo-
G in epigenetic modulation of gene transcription [192]. For more de-
tails on this topic, the interested reader is referred to an excellent recent
review [193].
These ﬁndings again demonstrate that most things in biology have
at least two sides: in the case of 8-oxo-G this seems to be a balance
between pro-mutagenic aspects, weighed up against possibly beneﬁcial
gene regulatory roles.
8. Relevance of oxidative stress and 8-oxo-G repair to disease
There has been a longstanding association between oxidative stress
and oxidative DNA damage with a wide variety of diﬀerent human
disorders, ranging from cancer, various neurodegenerative and neuro-
developmental disorders, inﬂammatory disorders to ageing (e.g. re-
viewed in [69,194–198]). Though for many of these associations the
initiating quality of oxidative stress on the onset of the disease is still
not absolutely proven, oxidative stress – and with it oxidatively da-
maged DNA – clearly seems to play a major role at least in disease
progression. Interestingly, oxidative stress and ROS are not only
thought to promote the development of cancer through generation of
mutations, but more recently it emerges that ROS have a quite central
role in cell growth signalling by inﬂuencing mitochondrial metabolism,
cellular proliferation as well as cellular stress responses (reviewed in
[195]). Indeed, ROS have been found to be an integral part of many
physiological signalling pathways, which can have just as important a
role in contributing to pathogenesis as direct mutations. Therefore, it is
reasonable to assume that the role of ROS in pathogenesis of many
diﬀerent disorders is a complex interaction between direct mutations
and activation of a variety of diﬀerent cellular pathways [199,200].
While these redox-signalling properties of ROS are highly interesting,
the focus of this review is on DNA damage, which is the reason that this
discussion remains restricted to ROS-generated mutations in DNA.
Single nucletoide polymorphisms (SNPs) in genes can cause a
change in the activity of a protein, either directly through structural
changes or for instance by alterations in its binding with interaction
partners, its expression, subcellular localisation or stability. For obvious
reasons, if such a change occurs in a DNA repair protein, this might
cause a build-up of DNA damage or mutations that in turn can pre-
cipitate the development of pathologies. Indeed, a plethora of poly-
morphisms in many diﬀerent DNA repair enzymes have been reported,
some of which were suggested to be associated with a propensity for
cancer development or been tied to the onset of neurodegenerative
diseases. While the data are quite clear on a very few select genes in
speciﬁc pathologies, for the majority of the proteins that are discussed
in the following the impact of the diﬀerent polymorphic variants to
human disease remains to be unequivocally proven. Due to the many –
often conﬂicting – epidemiological analyses and meta-analyses avail-
able I will not go into detail on every single reported polymorphism, but
rather try to focus on the more consolidated facts regarding ﬁndings
from in vivo studies using animal models or human patient samples.
8.1. 8-oxo-G repair relevance in vivo
8.1.1. Cancer
Genetic instability is one of the few enabling hallmarks of cancer,
and is thus considered indispensable for the development of tumours
[201]. It is therefore not surprising that oxidative stress and oxidative
DNA damage, known to lead to DNA damage and mutations, have been
intimately linked with cancer initiation and progression. Indeed, ele-
vates levels of ROS, and concomitant oxidative DNA damage have been
reported in almost all types of cancer, and manipulations of ROS levels
are being discussed as potential anticancer strategies (reviewed in
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[202–204]). Of note, many cancers have been found to harbour
C:G→ A:T transversion mutations, further underlining the importance
of 8-oxo-G in the development of cancer (e.g. [205]). C:G→ A:T mu-
tations have even been found to be frequent among germline and so-
matic mutations in both humans and mice [206]. Overall, cancer de-
velopment, biology and progression and oxidative DNA damage are
very tightly related.
To speciﬁcally analyse the contribution of 8-oxo-G repair to cancer
development in an in vivo model, there have been various studies as-
sessing the eﬀect of removing some of the key repair factors involved its
repair (Table 3). Investigations into the roles of OGG1 and/or MUTYH
in vivo using mice with targeted knockouts (KOs) of the respective genes
have been recently reviewed in detail [56,69]. In short, OGG1 single-
KO mice are viable and fertile, showing normal life span with no major
defects that can be observed [207,208]. In these mice 8-oxo-G accu-
mulated in nuclear and mitochondrial liver DNA, and an elevated
spontaneous C:G→ A:T transversion rates in some but not all tissues
was observed. There is possibly a slightly elevated predisposition for
lung cancer at 18 months after birth [209]. The apparent lack of ‘pro-
blems’ in mice lacking the major 8-oxo-G removing enzyme OGG1 was
slightly astonishing and suggested other backup mechanisms to be in
place to compensate loss of OGG1. Very recent data from a multiorgan
carcinogenesis bioassay using a variety of known genotoxic carcino-
genic agents that observed mice up to 34 weeks suggests however, that
OGG1 KO mice might indeed have an enhanced susceptibility for tu-
mour development in a variety of organs [210]. It thus seems that lack
of OGG1 can be largely compensated for under physiological circum-
stances, but this buﬀering capacity is not suﬃcient under conditions of
heightened threat to genetic integrity. MUTYH single-KO mice proved
to be viable, fertile and without major growth defects and normal life
span, with a slight predisposition to develop intestinal adenoma and
carcinoma at 18 months of age, which can be exacerbated by treatment
with oxidative stress inducing agents [211,212]. Again, accumulation
of 8-oxo-G was found to be organ dependent. Mice lacking both OGG1
and MUTYH, while viable and fertile, display a reduced life span and a
strong predisposition for tumours in lung and ovaries as well as lym-
phomas [211]. Interestingly, these mice also show an altered beha-
vioural and learning phenotype, which stems from diﬀerential gene
expression in the brain [213]. Deletion of MTH1 in mice results in a
slightly increased mutation rate, with tumours located to lung, liver and
stomach [214,215]. Taken together, these ﬁndings demonstrate that 8-
oxo-G repair seems to be more important in some tissues than others,
and that nature has many redundancies or backup mechanisms in place
to be able to compensate for the loss of one particular repair system
quite extensively. Nevertheless, the results from these animal studies
highlight the involvement of 8-oxo-G DNA damage and its repair in the
development of cancer.
It has to be mentioned that the KO of other important factors in-
volved in repair of 8-oxo-G, such as APE1, Pol β, XRCC1 Lig I and Lig III
is embryonically lethal, which is why studies assessing the impact of
these have not been performed (Table 3). Mice that are knockout for Pol
λ are viable and fertile, and lack any overt pathologies [216]. To the
best of my knowledge, these mice have not been analysed from the
perspective of cancer propensity, however. It should also be added here
that an initial report on Pol λ knockouts reported these mice to display
hydrocephalus, situs inversus and male infertility [217]. However, it is
generally thought nowadays that the targeting approach used in this
particular study ablated also adjacent parts of DNA other than Pol λ,
where genomic analysis predicted the existence of a transcribed gene
strongly conserved throughout evolution on the opposite strand, which
was most probably responsible for the observed phenotype [218].
8.1.2. Neurodegenerative disorders
There have been long-standing observations of increased oxidative
DNA damage, both in nuclear as well as mitochondrial DNA, in post
mortem samples from human brain regions aﬀected by neurodegen-
erative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease
(PD), Amyotrophic Lateral Sclerosis (ALS) and stroke (reviewed in
[225,226]). Also, oxidative stress has been linked to trinucleotide re-
peat (TNR) instability, a hallmark of Huntington’s disease (HD) (re-
viewed in [227]), and others. And ﬁnally, increased oxidative DNA
damage has also been implicated to play a causal role in neurodeve-
lopmental dysfunctions, such as autism spectrum disorder (ASD) and
schizophrenia (reviewed in [198]). Similarly to cancer, the cause-con-
sequence relationship has not been unequivocally established yet for all
of these disorders and oxidative DNA damage. Nevertheless, BER of
oxidative DNA damage certainly occupies a central role in the patho-
genesis of these disorders.
Taken together, there is an abundant amount of literature doc-
umenting the involvement of various diﬀerent BER proteins in human
diseases, a short overview of which is purveyed to the reader more in
detail in the following sections as well as in an overview in Table 4.
8.2. OGG1 and human diseases
While there are no reports about hereditary deﬁciencies or in-
activation of OGG1 in relation to a cancer predisposition phenotype in
humans, somatic mutations and polymorphisms in OGG1 that impact its
function have been numerously described in association with a variety
of diﬀerent types of cancer (recently reviewed in [69]). The impact of
DNA polymorphisms in OGG1 on cancer risk has been reviewed thor-
oughly [228]. Given its central role in the removal of 8-oxo-G from the
genome, it thus is very likely that OGG1 has a role in prevention of
cancer development in humans.
Interestingly, OGG1 has also been linked to the pathogenesis of
asthma (reviewed in [196]). Current research points to following me-
chanism underlying this phenomenon: free 8-oxo-G forms a complex
with OGG1 which subsequently activates RAS-family GTPases that lead
to an activation of the innate and adaptive immune systems, thus
leading to the pathological remodelling found in asthmatic patients.
Also other links between OGG1 and diseases involving an inﬂammatory
pathogenesis have been solidiﬁed lately (reviewed in [69]). And lastly,
changes in OGG1 levels as well as a polymorphism have been associated
with neurodegenerative disorders, such as AD, PD, ALS, HD and stroke/
ischemia (reviewed in [229]). Recently, a study investigating the ex-
pression of a panel of BER proteins in peripheral blood from 100 AD
patients and 110 healthy volunteers found signiﬁcant down-regulation
of OGG1 in patients, which was not due to diﬀerential methylation of
the gene promoter [230,231]. A possible association of SNPs in OGG1
and AD has been identiﬁed [232] and these SNPs altered OGG1 cata-
lytic activity and sensitized cells to DNA damage [233].
8.3. MUTYH and human disease
The evidence supporting the importance of correct repair of A:8-
Table 3
BER proteins and their knockout phenotypes.
Protein KO Phenotype Refs.
OGG1 Viable, fertile, slight predisposition for tumour
development; for details see text
[207,208]
MUTYH Viable, fertile, slight predisposition for tumour
development; for details see text
[211,212]
APE1 Embryonic lethal [219,220]
DNA polymerase β Embryonic lethal [221]
DNA polymerase λ Viable, fertile [216]
XRCC1 Embryonic lethal [222]
DNA ligase I Embryonic lethal (hematopoietic defects after
midterm)
[223]
DNA ligase III Embryonic lethal [224]
Table summarizing the BER proteins discussed throughout this manuscript and their
knockout phenotype.
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oxo-G mismatches via the MUTYH-initiated pathway to prevent human
disease has solidiﬁed signiﬁcantly over the last decade. Biallelic
germline mutations in MUTYH are known to cause a cancerous disease
termed MUTYH-associated polyposis (MAP) (reviewed in [56]). MAP
runs in families in an autosomal recessive mode and is characterized by
the formation of multiple colorectal adenoma and carcinoma as well as
an increased propensity to develop tumours of the ovaries, bladder, skin
and breast. MAP cases account for approximately 1% of all colorectal
cancer cases. Interestingly, no other genes that are involved in the re-
pair of oxidative DNA lesions have been associated with a multiple
colorectal adenoma phenotype thus far [234]. Carriers of biallelic
germline mutations in MUTYH were also found to be at higher risk for
extracolonic cancer at a variety of sites (e.g. [235,236]). Even hetero-
zygous germline mutations in MUTYH have been linked to a elevated
risk of colorectal cancer above the age of 55 [237]. Interestingly, tu-
mours from MAP patients show particular features of microsatellite
instable cancers similar to those arising from MMR deﬁciency [238], an
observation also seen in B-cell lymphoblastic lymphomas arising in
mice that are double-KO for msh2 and mutyh [239]. Further, the ex-
pression patterns of human leucocyte antigen I on tumour cells derived
from MAP patients was defective in 65% of tested primary carcinomas
and often associated with loss of expression of beta-2-microglobulin,
which again are features usually observed in MMR-defective tumours
[240]. In patients with colorectal cancer, an association of MUTYH and
MSH6 germline mutations has been described, suggesting that both
genes act cooperatively and a simultaneous deﬁciency in both might
possibly confer an increased risk for development of colorectal cancer
[241,242]. These ﬁndings were in contrast however to an earlier study
that did not ﬁnd any association between germline mutations of these
two genes in hereditary non-polyposis colon cancer patients [243]. Yet
another report suggested a possible mutual exclusivity of abrogation of
MSH6 and MUTYH in humans [244]. Finally, carriers of mutations in
both MUTYH as well as a MMR gene (MLH1, MSH2 or PMS2) were at
substantially higher risk to develop colorectal cancer than those car-
rying MUTYH mutations alone [245]. Concluding, while the ﬁnal ver-
dict of the interplay between MMR and MUTYH mutations in cancer
still awaits conﬁrmation, it seems likely, given all the in vitro and in vivo
data as well as the data from human patients that there is a strong
interplay between MMR and MUTYH-initiated BER in handling oxida-
tive DNA lesions, such as 8-oxo-G.
More recently, inactivation of MUTYH through germline mutations
has been found to be associated with other types of cancer than colon
carcinomas as well, such as breast cancer [246], pancreatic neu-
roendocrine tumours, but not pancreatic ductal adenocarcinomas
[247]. Furthermore, a germline mutation in MUTYH has been
associated with small intestinal neuroendocrine tumours [248]. The
same study also found an association between these tumours and
germline mutations in OGG1, but those results did not reach statistical
signiﬁcance. Of note, all reported tumours with involvement of MUTYH
mutations harbour characteristic C:G→ A:T mutational patterns, in-
dicative for the importance of the MUTYH-dependent repair pathway
that prevents 8-oxo-G-derived C:G→ A:T transversions. Germline mu-
tations in MUTYH have also been tied to high-grade pediatric gliomas
and pilomyxoid astrocytoma in infancy [249,250], castrate-resistant
prostate cancer [251], urinary tract cancer [252]. and non-BRCA her-
editary breast and/or ovarian cancer syndromes [253]. And lastly, a
very recent analysis of metastatic cancer found presumed pathogenic
germline mutations of MUTYH in 10 patients out of a cohort of 500
patients in total with a wide array of diﬀerent tumour types [254]. This
translated to 16% of all 63 presumed pathogenic germline mutations
found in the study to be located in the MUTYH gene, a number even
higher than that for BRCA2, CHEK2 (both 14%), and BRCA1 (8%). This
exciting ﬁnding propels MUTYH and its role in familial predisposition
to cancer in general, as opposed to being restricted to its hitherto well-
known role in colon cancer, into the limelight.
A reduction in MUTYH expression, along with reductions in OGG1
and MTH1, was recently published in a set of 63 cases of diﬀuse-type
adenocarcinoma of the gastric cardia [255], and in a cohort of 50 pa-
tients with hepatocellular carcinoma compared to 50 healthy controls
[256]. Similarly, MUTYH levels were signiﬁcantly decreased in about
two third of investigated prostate adenocarcinoma compared to non-
cancerous prostatic tissue, which led to a signiﬁcant increase of total
somatic mutations as well as C:G→ A:T transversions in the MUTYH
low expressing group [257]. Altered expression levels of MUTYH were
found to correlate with an increase in 8-oxo-G in ulcerative colitis-as-
sociated carcinogenesis, suggesting that an increase in MUTYH may
contribute to early carcinogenic events in this condition [258]. Indeed,
MUTYH was found to inﬂuence the inﬂammatory response in a mouse
model of ulcerative colitis, as mice with a MUTYH KO were much more
resistant to develop ulcerative colitis and had a much dampened re-
sponse in cytokine expression than their wild type counterparts [259].
This is in line also with the proposed role of MUTYH in eliminating
heavily damaged cells to safeguard the organism against carcinogen-
esis, as delineated further below [260]. Indeed, MUTYH was shown to
have a protective eﬀect against inﬂammation-induced colorectal car-
cinogenesis by mediating inﬂammatory responses that lead to the re-
moval of corrupted cells [261].
Mechanistically, MUTYH malfunction in cancer has been linked to
C:G→ A:T transversions in genes that are known proto-oncogenes, such
as APC, KRAS, or Ctnnb1 and other important cellular targets
Table 4
Overview of associations of BER-proteins with human disease.
Protein Associated human diseases
OGG1 - Various cancer types (Polymorphic variants and expression changes)
- Asthma
- Neurodegenerative disorders (AD, PD, ALS, HD, Stroke/ischemia)
MUTYH - MUTYH-associated polyposis (MAP) and various other types of cancer (Germline mutations)
- Neurodegenerative disorders (PD, Stroke/ischemia, AD, HD and other TNR expansion disorders, Friedreich’s ataxia)
APE1 - Various cancer types (levels correlate with tumour aggressiveness)
- Neurodegenerative disorders (AD, PD, HD, ALS, Ataxia with Oculomotor Apraxia Type 1, cerebral ischemia)
DNA polymerase β - Possibly involved in tumour formation (deregulated levels in tumours and evidence for pathogenic polymorphisms)
- Neurodegenerative disorders (AD, HD, stroke/ischemia)
DNA polymerase λ - Possibly involved in tumour formation (deregulated levels in tumours and evidence for pathogenic polymorphisms)
XRCC1 - Various cancer types (deregulated levels in tumours and evidence for pathogenic polymorphisms)
- Neurodegenerative disorders (AD, HD, stroke/ischemia, progressive cerebellar ataxia, ocular motor apraxia and peripheral axonal neuropathy)
- Epilepsia, Down’s syndrome
DNA ligase I - Various cancer types
- TNR expansion disorders
DNA ligase III - Various cancer types
Table summarizing the BER proteins discussed throughout this manuscript and their associations with human diseases. For references see detailed text sections.
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[258,262–267]. This ﬁnding is in accordance with the well-established
role of MUTYH to prevent 8-oxo-G mediated mutagenesis. A very recent
analysis revealed signiﬁcantly more protein-changing somatic muta-
tions, truncating mutations and copy number variants in duodenal
adenomas from MAP patients compared to adenomas from patients
suﬀering from familial adenomatous polyposis, another inherited dis-
order characterised by colorectal polyposis and cancer [267]. The au-
thors thus conclude that MAP patients might thus even be at higher
cancer risk in the context of apparently benign disease, which has im-
plications for clinical management of these patients.
Interestingly however, apart from its protective role against muta-
tions, MUTYH is also slowly emerging to be an initiator of programmed
cell death in states of oxidative stress to suppress tumourigenesis by
driving eﬃcient elimination of cells with high 8-oxo-G levels (reviewed
in [260]). This is achieved by transcriptional up-regulation of MUTYH
through p53, upon which the heightened cellular MUTYH-incision ac-
tivity causes an accumulation of SSBs in the nuclear as well as the
mitochondrial DNA, which in turn lead to PARP1/MLH1- or calpain-
dependent execution of apoptosis, respectively [268]. This pro-apop-
totic activity of MUTYH has also been noted with the combination of
the UVA photosensitiser 6-thioguanine and UVA, as a deﬁciency in
MUTYH rendered cells (and mice) more resistant to this synergistically
cytotoxic treatment regime [269]. Therefore, it seems that MUTYH has
a dual role in protecting organisms against tumour formation: on one
hand it serves with its DNA repair capacity to avoid mutations from
forming, and on the other hand it acts as a ‘cellular thermostat’ for
oxidative DNA damage, which triggers apoptosis upon accumulation of
too many DNA lesions. In light of this, it is interesting to note that, to
the best of my knowledge, there has not been a single report showing
overexpression of MUTYH in cancer.
The involvement of MUTYH in neurological disorders is somewhat
less analysed. It has been implicated in PD and stroke/ischemia, but
further research is required to solidify this evidence and further our
understanding of the role of MUTYH in the brain (reviewed in [229]).
Repair of 8-oxo-G lesions by MUTYH was demonstrated to be re-
sponsible for triggering neurodegeneration through activation of
apoptotic signalling that leads to exacerbated microgliosis, and sug-
gested that suppression of MUTYH during conditions of oxidative stress
might confer protection of brain tissue [270]. Recently, a study in-
vestigating the expression of a panel of BER proteins in peripheral blood
from 100 AD and 110 healthy volunteers found signiﬁcant down-reg-
ulation of MUTYH in patients, which was not caused by diﬀerential
methylation of the gene promoter [230]. The involvement of MUTYH in
initiation of neurodegeneration in the context of AD has been discussed
in [271]. Recently, a combination of oxidised dNTP pools and the
subsequent repair by OGG1 and MUTYH was shown to cause TNR in-
stability, which is the causal molecular event underlying HD and other
TNR expansion disorders [272]. Also, a combined deﬁciency of OGG1
and MUTYH caused an acceleration in the clinical course of prion dis-
ease, suggesting that accumulating oxidative DNA damage might ex-
acerbate the ﬁnal toxic phase of the disease [273]. And ﬁnally, MUTYH
was demonstrated to be involved in microglial activation that is in-
itiated by DNA damage in a mouse model of Friedreich’s ataxia [274].
8.4. APE1 and human diseases
Data implicating malfunction of APE1 in a variety of human dis-
eases is quite extensive and has recently been thoroughly reviewed
recently [275]. For instance, elevated expression of APE1 has been
found in many tumours and in many cases seems to be associated with
cancer aggressiveness and resistance against chemo- and radiotherapy
in a variety of diﬀerent cancers. The impact of DNA polymorphisms in
APE1 on cancer risk has been reviewed thoroughly [228]. Due to the
multifunctional nature of the APE1 protein− acting as redox signalling
factor as well as a key player in BER, where it is the main responsible
for generation of single strand breaks in the cell, it is not surprising that
APE1 emerges as a central player in protecting against oncogenic
transformation. Other than in cancer, increases in APE1 levels were
found to generate microsatellite instability in chronic inﬂammatory
diseases, such as ulcerative colitis [276].
The relationship between APE1 and central nervous pathologies has
been rather widely investigated. Changes in APE1 levels can be found in
patients with AD, PD, HD, ALS, Ataxia with Oculomotor Apraxia Type 1
and cerebral ischemia (reviewed in [229,275]). Taken together, these
ﬁndings point to a central role of APE1 in the maintenance of human
physiology, reﬂecting its many diﬀerent cellular functions. Recently, a
study investigating the expression of a panel of BER proteins in per-
ipheral blood from 100 AD patients and 110 healthy volunteers found
signiﬁcant down-regulation of APE1 in patients, which was not due to
diﬀerential methylation of the gene promoter [230].
8.5. DNA polymerase β and human diseases
Several small-scale sequencing studies have found 30–40% of
human tumours of diﬀerent origins to harbour mutations in Pol β
[277,278]. Also, a few polymorphic variants of Pol β have been iden-
tiﬁed in the human population. The eﬀect of some of these poly-
morphisms and diﬀerent mutations found in various cancers have been
analysed in more detail. Indeed, some of them can induce DNA damage,
mutations or even cellular transformation of cells, suggesting that these
mutants can causally contribute to tumour development (reviewed in
[279]). More than 2-fold overexpression of Pol β on protein level was
found in 29% of all tumour samples compared to matched normal
tissue, while lower than 0.5-fold under-expression was found in 20% of
all tested tumours. Diﬀerential expression of Pol β has also been noted
several other studies [280–282]. While most of these results are not
able to directly delineate a causal role of mutated or mis-regulated Pol β
in cancer pathogenesis in humans, they are highly interesting and fur-
ther investigations into the subject are warranted.
Apart from cancer, Pol β has been suggested to be involved in the
pathogenesis of AD, HD as well as stroke/ischemia (reviewed in [229]).
8.6. DNA polymerase λ and human diseases
Currently, there are 2 single nucleotide polymorphisms in Pol λ that
may be associated with breast cancer – T221P and R438W [283]. While
there has not been any functional follow-up information on T221P, Pol
λ R438W was originally found when screening several normal and
tumoural cDNA samples for polymorphisms, and was demonstrated to
have a reduced base substitution ﬁdelity, increase the mutation fre-
quency, generate chromosomal aberrations and compromise the
homologous repair pathway especially in response to camptothecin
treatment [284,285]. Interestingly, another study found this Pol λ
R438W to be signiﬁcantly enriched in the germlines of breast cancer
patients [286]. When cells were exposed to estrogen – which induces
ROS and thus 8-oxo-G lesions in cells – Pol λ R438W-mediated bypass
of 8-oxo-G lesions was not error-free and led to an increase in muta-
genesis as well as replicative stress, suggesting that this polymorphism
could increase the propensity to develop estrogen-associated breast
cancer.
A study investigating mRNA expression levels in 68 untreated
samples of diﬀerent types of cancer found Pol λ to be overexpressed in
24% of the analysed cancers and to be under-expressed instead in 16%
of them [100]. Similarly, an analysis of Pol λ levels in the bronchiolar
epithelium found a signiﬁcant correlation between expression of Pol λ
and habitual smoking in patients with lung cancer [287]. While intra-
tumoural expression of Pol λ failed to correlate with the smoking status,
tumours in heavy smokers that did not express Pol λ were at a sig-
niﬁcantly more advanced clinical stage. These ﬁndings suggested that
Pol λ might be involved in the repair of tobacco-smoke derived DNA
damage in the respiratory system. Interestingly, cigarette smoke is a
complex mixture consisting of over 3′500 harmful compounds, among
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which can be found high levels of free radicals and ROS [288]. Indeed,
a study found 34% of all identiﬁed somatic substitutions to be
C:G→ A:T transversion mutations in a small cell lung cancer cell line,
suggestive of 8-oxo-G mediated mutagenesis [289]. Furthermore, an
analysis of 518 protein kinase genes in 210 diﬀerent human cancers
detected 1007 somatic mutations, of which a large part were C:G→ A:T
transversions, especially in breast, lung and ovarian cancer [205].
Summarizing, there is evidence for a role of Pol λ and its involvement
in mitigating 8-oxo-G induced mutagenesis in preventing tumour de-
velopment, especially in breast and lung tissue.
8.7. XRCC1 and human diseases
As XRCC1 has a key role in coordination of BER, dysfunctions in this
protein have been abundantly suggested to be involved in cancer for-
mation. Indeed, an accumulation of unrepaired SSBs, caused e.g.
through defective or insuﬃcient DNA single-strand break repair, has
been suggested to mechanistically cause the very ﬁrst steps of carci-
nogenesis [115,290].
The impact of diﬀerent DNA polymorphisms in XRCC1 on cancer
risk has been reviewed thoroughly [228]. On a mechanistic level, one of
the most predominant XRCC1 polymorphic variants, R280H, was found
to result in increased focus formation in mouse C127 cells and to induce
cellular transformation in human MCF10A cells [291]. Indeed, cells
expressing this variant had signiﬁcantly more chromosomal aberrations
and double strand breaks, suggesting that individuals carrying this
mutation might be at increased risk of cancer development.
Literature addressing the expression levels of XRCC1 in cancer is
abundant. Immunohistochemical (IHC) detection found high expression
of XRCC1, among some other BER proteins, to correlate with high T-
stage (in the TNM staging), to lymph node positivity, and poor disease-
free survival in a total of 142 gastric adenocarcinomas [292]. Similarly,
another study using IHC found XRCC1 protein signiﬁcantly down-
regulated in a training cohort of 80 gastric carcinoma, which was tested
in a cohort of 374 patients and validated in an independent cohort of
385 patients [293]. However, in contrast to the previous report, this
study found XRCC1 levels signiﬁcantly correlated with overall survival,
so that the high XRCC1 expressing tumours had a longer overall sur-
vival. Furthermore, the XRCC1 low expressing group signiﬁcantly
proﬁted from platinum-based chemotherapy. Another study addressing
612 specimen of gastric cancer found no signiﬁcant correlation between
XRCC1 expression levels and overall- or disease free survival [294].
However, patients with negative XRCC1 expression seemed to beneﬁt
more from platinum-based adjuvant chemotherapy.
High XRCC1 mRNA levels in esophageal squamous cell carcinoma
were correlated with longer median overall survival [295]. High mRNA
levels of XRCC1 emerged as an independent prognostic factor for ESCC
patients using a multivariate analysis. While no association could be
found for XRCC1 expression and clinico-pathological features of eso-
phageal squamous cell carcinoma in another study, tumours positive for
RASSF1 and negative for XRCC1 were correlated with a longer median
overall- and progression-free survival [296].
In a panel of 50 Head and Neck Squamous cell carcinomas (HNSCC)
and controls, a statistically signiﬁcant down-regulation of RNA levels of
XRCC1 was found in tumours, and XRCC1 levels were negatively cor-
related to Ki-67 levels, increased levels of which are indicative of cel-
lular proliferation [297]. Additionally, XRCC1 levels were positively
correlated with OGG1 levels in this study.
RNA expression levels of XRCC1, and also OGG1, were signiﬁcantly
lower in a cohort of 75 HNSCC compared to control tissue, and XRCC1
and 8-oxo-G levels were negatively correlated [298]. Further, multi-
variate logistic regression analysis demonstrated that low expression of
XRCC1 an OGG1 was associated with a statistically signiﬁcant increase
in the risk of HNSCC.
Lower expression of XRCC1, quantiﬁed by RT-qPCR as well as
Western blotting, was found both in 40 samples of squamous
intraepithelial lesions (SIL) as well as 50 samples of invasive squamous
cell carcinoma of the cervix (CC), as compared to 85 control subjects
[299]. By using a multivariate logistic regression analysis, low expres-
sion of XRCC1 was signiﬁcantly associated with an increased risk for
both SIL and CC.
An analysis of 1′297 cases of early breast cancer, succeeded by va-
lidation in an independent cohort of 281 estrogen receptor α negative
breast cancers found loss of XRCC1 expression in 16% of cases, which
was signiﬁcantly associated with high grade, loss of hormone receptors,
triple negative tumours and basal-like phenotypes, and a two-fold in-
crease in risk of death as well as poor outcome [300]. Thus, loss of
XRCC1 expression seemed to lead to an aggressive phenotype. This
study also showed preclinical data of a synthetic lethality between
XRCC1 deﬁcient cancer cells and a DNA double-strand repair inhibitor.
Further investigation of XRCC1 protein expression in two cohorts of
1620 sporadic and 50 germ-line BRCA1 mutated breast cancer samples,
and mRNA expression in 1952 and 249 samples, respectively, revealed
that BRCA1 negativity was strongly associated with a low XRCC1 ex-
pression both at mRNA and protein levels [301]. In BRCA1 negative
tumours, a low expression of XRCC1 was signiﬁcantly associated with
poor survival compared to high XRCC1 expressing BRCA1 negative
tumours, suggesting that XRCC1 expression status might have prog-
nostic signiﬁcance in BRCA1 negative tumours. In contrast, the same
group found XRCC1 expression in ovarian tumours to be associated
with higher disease stage and platinum resistance, as well as a two-fold
increase in the risk of death [302]. Thus, XRCC1 expression in this
setting was associated with adverse clinico-pathological and survival
outcomes in patients, and non-platinum-based treatment of XRCC1
positive tumours should be considered. In a cohort of 1′269 breast
cancers, and validated in an independent estrogen-receptor α negative
cohort of 279 cases, XRCC1 low-expressing patients had high numbers
of CD8+ tumour-inﬁltrating lymphocytes, but were also signiﬁcantly
linked to higher grades, proliferation indexes, presence of dediﬀer-
entiated cells and poor survival [303]. Furthermore, PD-1+ or PD-L1+
breast cancers that displayed low XRCC1 were more aggressive, sug-
gesting an interplay between DNA repair and immune checkpoints in
the biology of breast cancer. Interestingly, a study analysing 40 women
with newly diagnosed breast cancer, of which 20 had acute side-eﬀects
after radiotherapy and 20 did not, found that XRCC1 levels were sig-
niﬁcantly lower in the group with acute side-eﬀects [304]. These results
suggested that a decrease in XRCC1 might be associated with an in-
creased risk of radiotherapy-induced acute side eﬀects in breast cancer
patients.
Non-small cell lung cancer (NSCLC) patients with low XRCC1 mRNA
levels were found to have a higher response rate to chemoradiotherapy
compared to those with high expression levels [305].
IHC analysis of 157 locally advanced bladder cancer samples that
had received combined trimodality therapy found that patients positive
for XRCC1 expression exhibited signiﬁcantly better disease-speciﬁc
survival rates [306]. Measurements of XRCC1 mRNA levels in 52 spe-
cimen of primary urothelial carcinoma of the bladder found increases in
XRCC1 signiﬁcantly associated with higher grade tumours [282].
IHC assessment of XRCC1 expression on a tissue microarray with
119 melanoma samples, loss of XRCC1 was associated with progression
of the disease (from dysplastic nevi to primary and metastatic mela-
noma) [307]. XRCC1 loss further also correlated with worse overall and
disease-speciﬁc 5- and 10-year survival.
High nuclear expression of XRCC1, determined by IHC of 160
biliary tract cancer samples, was much lower in neoplastic tissues than
control tissues [308]. Furthermore, high nuclear expression was found
to positively correlate with overall survival, and patients with high
cytoplasmic expression of XRCC1 had signiﬁcantly more lymph node
metastasis and a worse overall survival, and more vascular invasion
could be seen in low nuclear expressing cases.
And ﬁnally, XRCC1 mRNA levels were found to be signiﬁcantly
lower in hepatocellular carcinomas than control tissues [256].
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In conclusion, while there is a plethora of data regarding XRCC1
expression levels in many diﬀerent types of cancer, there is still a lack of
complete understanding as to what extent and how XRCC1 levels cor-
relate with disease progression. Future investigations will hopefully
bring clariﬁcation to its exact role in carcinogenesis.
The involvement of XRCC1 in neurological diseases has garnered a
bit less attention than is connection to cancer, however there is a
variety of very interesting ﬁndings regarding this connection which
have mostly been reviewed in [229]. Brain-speciﬁc KO animals for
XRCC1 (driven by Nestin-Cre) show age-dependent accumulation of
DNA damage, loss of cerebellar interneurons and altered hippocampal
homeostasis [309].
Changes in XRCC1 levels have been associated with AD, models of
HD, stroke/ischemia and epilepsia, as well as in brains of Down’s syn-
drome patients (reviewed in [229]). Similarly, a partial loss of XRCC1
was shown to result in increased brain damage and impaired recovery
from ischemic stroke in a mouse model [310]. By far the most con-
vincing report of XRCC1’s importance in development and maintenance
of the central nervous system comes from the Caldecott lab, which
identiﬁed the ﬁrst ever reported patient carrying a biallelic mutation in
XRCC1 that almost completely deletes the protein, most likely by trig-
gering nonsense-mediated mRNA decay through premature stop codons
[311]. These mutations are associated with progressive cerebellar
ataxia, ocular motor apraxia and peripheral axonal neuropathy.
8.8. DNA ligases I and III and human diseases
A complete KO of Lig I was found to cause embryonic death at mid-
gestation because it is required for fetal liver erythropoiesis [223]. In-
terestingly, this result suggested that replication can be performed even
in the absence of Lig I. Mice with a point mutation in the Lig I gene
found in a human cancer patient displayed an increased incidence of a
diverse range of spontaneous epithelial tumours, along with replication
failure and genome instability [312]. Interestingly, inactivation of Lig
III did not cause repair defects in nuclear DNA, but resulted in loss of
mitochondrial DNA, suggesting it was dispensable for nuclear DNA
repair [313]. Instead, Lig I was critical for nuclear DNA repair, in a
cooperative manner with Lig III.
Expression of Lig I, as determined by Western blot of extracts from
various human malignant cancer specimen, was found to be elevated in
human cancers, suggesting it played an important role in proliferating
cells [314]. Lig IIIa, the nuclear isoform of Lig III, was shown to be up-
regulated in chronic myeloid leukemia, which possibly contributes to
disease progression [315].
Expression patterns of both ligases in the brain have been reviewed
in [229]. TNR expansion has been tied to activity of DNA ligase I
[316–322].
SNPs of both ligases have been implicated to play a role in cancer
and neurodegenerative diseases, but larger validation studies are still
missing for conclusive evidence.
8.9. MTH1 and human diseases
To date, no germline mutations of MTH1 have been reported in the
context of cancer. Interestingly, an increased expression of MTH1 cor-
relates with malignancy of tumours, suggesting that tumour cells rely
strongly on sanitisation of their nucleotide pools for proper growth
(reviewed in [72]). Inhibition of MTH1 was proposed as an attractive
cancer-drug target [323,324], but this ﬁnding has been hotly debated
and opposing results have accumulated since [325–327]. Thus, it re-
mains to be established how far cancer cells really rely on MTH1 ac-
tivity.
In contrast to its involvement with cancer in humans, the role of
MTH1 in the protection of brain tissue has been widely analysed. Ties
between MTH1 and neurodegenerative diseases, such as Alzheimer’s
disease [328–330] and Parkinson’s disease [331,332] exist, suggesting
that MTH1-mediated nucleotide pool sanitisation is important in the
protection against various brain pathologies (reviewed in [72]).
9. Conclusions and perspectives
Oxidative DNA damage, and in particular 8-oxo-G has garnered
much attention over the last decades. The mechanisms underlying its
repair are being progressively unveiled in detail owing to extensive
eﬀorts by a large number of contributing investigators. While the basic
framework built of understanding the underlying biochemical reactions
and interactions of the diﬀerent players is very solid, much still needs to
be done to ﬁll in the more complicated or perhaps just less explored
details that are essential for an integrated comprehension of the cellular
systems that lead to safekeeping of the genome. In particular, deeper
insights into the organisation of oxidative DNA damage repair in the
context of the living cell should be aspired. Questions include, but are
certainly not limited to: where exactly does oxidative DNA damage
accumulate? How are diﬀerent aspects of its repair regulated in the
context of the cell cycle, especially during S-phase? How do these well-
deﬁned repair pathways perform in the context chromatin? What in-
ﬂuence does chromatin remodelling have on these reactions? How is
the interplay between the various diﬀerent and sometimes overlapping
repair activities managed? What are there more profound tissue- and
cell-type speciﬁc diﬀerences in these mechanisms that underlie the
diﬀerences in disease predisposition? Unravelling these riddles will
necessitate considerable eﬀorts, but is expected to yield important in-
sights to further clarify the connection between oxidative DNA damage,
its repair and human diseases. Considering the clear involvement of
oxidative DNA damage repair in the onset and pathogenesis of many
diﬀerent human pathologies, more detailed understanding of these
mechanisms in the context of the organism might well pave the way for
successful preventive and therapeutic approaches involving the repair
of oxidatively damaged DNA.
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